EP0828839A1 - Animal gene therapy - Google Patents
Animal gene therapyInfo
- Publication number
- EP0828839A1 EP0828839A1 EP96913403A EP96913403A EP0828839A1 EP 0828839 A1 EP0828839 A1 EP 0828839A1 EP 96913403 A EP96913403 A EP 96913403A EP 96913403 A EP96913403 A EP 96913403A EP 0828839 A1 EP0828839 A1 EP 0828839A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- dna
- expression
- gene
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241001465754 Metazoa Species 0.000 title claims description 68
- 238000001415 gene therapy Methods 0.000 title abstract description 32
- 108020004414 DNA Proteins 0.000 claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 19
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 65
- 235000018102 proteins Nutrition 0.000 claims description 49
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 44
- 210000004907 gland Anatomy 0.000 claims description 35
- 208000015181 infectious disease Diseases 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 108020005544 Antisense RNA Proteins 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 108010062877 Bacteriocins Proteins 0.000 claims description 17
- 241000283690 Bos taurus Species 0.000 claims description 17
- 230000009261 transgenic effect Effects 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 239000003184 complementary RNA Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 15
- 239000002502 liposome Substances 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 10
- 230000003248 secreting effect Effects 0.000 claims description 9
- 230000001177 retroviral effect Effects 0.000 claims description 8
- -1 lanthionins Proteins 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 102000011632 Caseins Human genes 0.000 claims description 6
- 108010076119 Caseins Proteins 0.000 claims description 6
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 210000003292 kidney cell Anatomy 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 5
- 239000002955 immunomodulating agent Substances 0.000 claims description 5
- 229940121354 immunomodulator Drugs 0.000 claims description 5
- 102000004407 Lactalbumin Human genes 0.000 claims description 4
- 108090000942 Lactalbumin Proteins 0.000 claims description 4
- 102000010445 Lactoferrin Human genes 0.000 claims description 4
- 108010063045 Lactoferrin Proteins 0.000 claims description 4
- 102000008192 Lactoglobulins Human genes 0.000 claims description 4
- 108010060630 Lactoglobulins Proteins 0.000 claims description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 4
- 235000021242 lactoferrin Nutrition 0.000 claims description 4
- 229940078795 lactoferrin Drugs 0.000 claims description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 3
- 241000282324 Felis Species 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002955 secretory cell Anatomy 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 108050004290 Cecropin Proteins 0.000 claims description 2
- 108010002069 Defensins Proteins 0.000 claims description 2
- 102000000541 Defensins Human genes 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108060003100 Magainin Proteins 0.000 claims description 2
- 102000029797 Prion Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 108010076830 Thionins Proteins 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 108010087689 lacticin 481 Proteins 0.000 claims description 2
- SRCAXTIBNLIRHU-JJKPAIEPSA-N lantibiotic pep5 Chemical compound N([C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N\C(=C/C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N\C(=C(/C)S)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](C)NC(=O)C(=O)CC SRCAXTIBNLIRHU-JJKPAIEPSA-N 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000000663 muscle cell Anatomy 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 235000017709 saponins Nutrition 0.000 claims description 2
- 101150099695 vps11 gene Proteins 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims 4
- 235000021241 α-lactalbumin Nutrition 0.000 claims 3
- 108050001786 Alpha-s2 casein Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- 239000005018 casein Substances 0.000 claims 2
- 235000021247 β-casein Nutrition 0.000 claims 2
- 102100035687 Bile salt-activated lipase Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 101710087237 Whey acidic protein Proteins 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 108010087173 bile salt-stimulated lipase Proteins 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 230000001254 nonsecretory effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 235000021246 κ-casein Nutrition 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 abstract description 27
- 239000000203 mixture Substances 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 241000124008 Mammalia Species 0.000 abstract description 4
- 238000002513 implantation Methods 0.000 abstract description 2
- 238000011065 in-situ storage Methods 0.000 abstract description 2
- 108090000988 Lysostaphin Proteins 0.000 description 52
- 210000005075 mammary gland Anatomy 0.000 description 42
- 108010000521 Human Growth Hormone Proteins 0.000 description 37
- 235000013336 milk Nutrition 0.000 description 36
- 239000008267 milk Substances 0.000 description 36
- 210000004080 milk Anatomy 0.000 description 36
- 102000002265 Human Growth Hormone Human genes 0.000 description 34
- 239000000854 Human Growth Hormone Substances 0.000 description 34
- 241000283707 Capra Species 0.000 description 32
- 241001494479 Pecora Species 0.000 description 18
- 238000013459 approach Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000006651 lactation Effects 0.000 description 15
- 241000191967 Staphylococcus aureus Species 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 235000013365 dairy product Nutrition 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 208000035240 Disease Resistance Diseases 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 5
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000191978 Staphylococcus simulans Species 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 230000001524 infective effect Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 229940037648 staphylococcus simulans Drugs 0.000 description 5
- 241000714266 Bovine leukemia virus Species 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000000510 mucolytic effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000001082 somatic cell Anatomy 0.000 description 4
- 230000000392 somatic effect Effects 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 241000282849 Ruminantia Species 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108700026226 TATA Box Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 241000713325 Visna/maedi virus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 235000020251 goat milk Nutrition 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 210000003622 mature neutrocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000001662 opsonic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000283726 Bison Species 0.000 description 2
- 208000031462 Bovine Mastitis Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 206010051497 Rhinotracheitis Diseases 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000010094 Visna Diseases 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000009215 host defense mechanism Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000020254 sheep milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 108010087945 whey acidic proteins Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FHYNZKLNCPUNEU-UHFFFAOYSA-N 4-[(3,4-dihydroxyphenyl)methyl]-3-[(4-hydroxyphenyl)methyl]oxolan-2-one Chemical compound C1=CC(O)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(O)=C1 FHYNZKLNCPUNEU-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000606801 Actinobacillus lignieresii Species 0.000 description 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000186225 Corynebacterium pseudotuberculosis Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000795424 Epia Species 0.000 description 1
- GDSYPXWUHMRTHT-UHFFFAOYSA-N Epidermin Natural products N#CCC(C)(C)OC1OC(CO)C(O)C(O)C1O GDSYPXWUHMRTHT-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108090001102 Hammerhead ribozyme Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100034353 Integrase Human genes 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000194035 Lactococcus lactis Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010058096 Pancreatic necrosis Diseases 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108020005089 Plant RNA Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091006619 SLC11A1 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 101100510631 Staphylococcus epidermidis epiA gene Proteins 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 240000001068 Thogoto virus Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000186064 Trueperella pyogenes Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 101000756604 Xenopus laevis Actin, cytoplasmic 1 Proteins 0.000 description 1
- 208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002776 alpha toxin Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940046545 animal allergen extract Drugs 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000000753 anti-hemolysin Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 101150090305 beg gene Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 239000007478 blood agar base Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108040002566 cell-cell adhesion mediator activity proteins Proteins 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 108010064962 epidermin Proteins 0.000 description 1
- CXTXHTVXPMOOSW-JUEJINBGSA-N epidermin Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CSC[C@H](C(N[C@@H](CCCCN)C(=O)N1)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@H]1C(N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CS[C@H]1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N\C(=C/C)C(=O)NCC(=O)N[C@H]1C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@H](C(N\C=C/SC2)=O)CSC1)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 CXTXHTVXPMOOSW-JUEJINBGSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000011239 genetic vaccination Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 229940090046 jet injector Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 201000009837 laryngotracheitis Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/103—Ovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
Definitions
- the invention relates to DNA sequences, expres ⁇ sion cassettes and DNA constructs for use in therapy, specifically in gene therapy for the treatment of infectious diseases such as mastitis. Also included are pharmaceutical and veterinary compositions containing the constructs, and cells which have been transformed with the DNA and which are suitable for implantation into a host mammal.
- transgenic animals are the principal way to confer transmissible resistance to diseases in animals. Only few years after the first successful gene transfer into mice the new technique was used in farm animals. Several genetic treats have been targeted for the application of transgenesis in domestic animals, but one of those important aspects is the improvement of animal health and disease resistance by gene transfer means. Transient as well as stable genetic improvement leading to disease resistance and treatment achieved by recently developed techniques in molecular biology may contribute considerably to reduce the problem of diseases.
- candidates for gene therapy applications include all genes known to modulate non-specific and specific host defense mechanisms, i.e. cytokines, major histocompatibility complex (MHC) proteins, T-cell receptors (TCR) and proteins conferring specific dis- ease resistance. Increased protection against patho ⁇ gens can be conferred also by other strategies such as "intracellular immunization", genetic immunization, antisense sequences as anti-pathogenic agents and dis- ruption of disease susceptibility genes.
- MHC major histocompatibility complex
- TCR T-cell receptors
- Interferon Interferon
- IFNs Interferon
- IFNs Interferon
- the proteins known to be involved in the antiviral and bac- tericidal actions of interferon and their inhibitory mechanisms are numerous.
- the potency of IFNs to posi- tively influence host susceptibility to viral infec ⁇ tions was tested in transgenic mice and cell lines. Transgenic organisms overexpressing IFN- ⁇ gene con ⁇ structs were shown to exhibit enhanced viral resis- tance.
- IFNs interferon-stimulated gene factor
- IRF-1 interferon regulatory factor
- Mxl gene product of certain mouse strains.
- the mouse Mxl protein belongs to a family of polypeptides with GTPase activity synthesized in IFN-treated verte ⁇ brate cells. Some Mx proteins have been shown to block the multiplication of certain negative-stranded RNA viruses, as for example Influenza virus , VSV, rhado virus and Thogoto virus. Synthesis of mouse Mxl pro ⁇ tein in various cell lines and transgenic mice demon ⁇ strated that it is both necessary and sufficient to promote resistance to influenza A viruses in previously susceptible cells and animals. The cloning and func- tional characterization of this specific disease resis ⁇ tance gene enabled a gene transfer program to study whether Mxl transgenic pigs would show reduced suscep ⁇ tibility to influenza infections.
- Natural resistance of certain inbred mouse strains to infection with antigenetically unrelated microorganisms such as Mycobacteria , Salmonellae and Leishmania is controlled by a dominant locus on chromo ⁇ some 1 called Beg, Lsh or Ity respectively.
- the locus affects the capacity of the host to restrict prolifera ⁇ tion of these infectious pathogens during the non-spe- cific macrophage-dependent phase of infection.
- a posi ⁇ tional cloning approach resulted in the isolation of a candidate Beg gene designated Nramp.
- the reduction of susceptibility to Salmonella infections by transgenesis or gene therapy ( in vivo or ex vivo) means is of great value for animal production, especially poultry.
- Fv-4 encoding only the viral envelope protein in transgenic mice conferred resistance to infection with ecotropic retroviruses.
- the mechanism of Fv-4 resistance is thought to be related to the phenomenon of viral interference, i.e. competition of the synthesized envelope protein with exogenous virus for the virus receptor. Similar mecha ⁇ nisms are used in antiviral strategies known as "intracellular immunization".
- transgene encoding an immu- noglobulin specific for a common pathogen can provide immunity for that pathogen.
- cloned genes coding for monoclonal antibodies can be expressed in large amounts in genetically manipulated mice. These mice produce antibodies against specific antigens without prior contact or immunization.
- MMTV mouse mammary tumor virus
- intracellular immunization is also applied for antiviral strategies described in different connections such as expression of specific resistance genes, antisense RNAs or other antiviral components.
- Transgenic sheep were produced and were shown express ⁇ ing the visna virus envelope ( env) gene.
- the visna virus belongs to a subfamily of ovine retroviruses that cause encephalitis, pneumonia and arthritis in sheep.
- the env glycoprotein is responsible for the binding of this virus to host cells.
- the target cell for visna virus replication in infected sheep is the macrophage.
- the expression of env protein on the cell surface of visna-infected cells induces immune responses to the virus.
- Expression of a gene construct consisting of the visna U3 enhancer region fused to the env gene in transgenic sheep had no obvious deleterious effect.
- the genetically manipulated sheep lines provide an evidence for the potential of a retroviral env gly ⁇ coprotein to prevent infection and/or to modulate dis- ease in its natural host after virus challenge.
- antisense RNA functions by binding in a highly specific manner to complementary sequences, thereby blocking the ability of the bound RNA to be processed and/or translated. Antisense sequences are considered an attractive alter- native to conventional drugs in the therapy of micro- bial infections, cancer, autoimmune diseases and other malfunctions. Gene transfer experiments with antisense constructs have been carried out in mice and rabbits. Genetically manipulated mice expressing antisense RNA targeted to the retroviral packaging sequences of Molony murine leukemia virus did not develop leukemia following challenge with infectious viruses.
- Trans ⁇ genic rabbits expressing an antisense construct comple ⁇ mentary to adenovirus h5 RNA were produced. Primary cells from these rabbits were found to be 90-98% more resistant to adenovirus infection than cells from con ⁇ trol animals.
- antisense RNAs as anti-parasitho- genic agents can be developed to result not only in RNA-RNA hybrids but catallytically cleave a phosphodi- ester bound in the target RNA strand.
- Four structural motifs hammerhead and hairpin first identified in plant RNA pathogens, the delta motif found in human hepatitis delta virus and a less well characterized motif from Neuspora ) have thus far been described as intermediates in these self-cleavage reactions.
- the hammerhead motif of this ribozyme family By flanking the hammerhead motif of this ribozyme family with antisense sequences, the cleavage of specific tar ⁇ get RNAs has been demonstrated.
- Bovine leukemia virus (BLV), a retrovirus , causes persistent lymphocytosis and B-lym- phocyte lymphoma in cattle and sheep.
- BLV bovine leukemia virus
- a hammerhead ribozyme flanked by antisense sequences directed against regulatory proteins of BLV was shown to inhibit BLV expression in persistently infected cells. This demonstrates the possibility of generating localized ( in vivo or ex vivo) or generalized (transgenic ani ⁇ mals) gene therapies that will be resistant to BLV- induced diseases.
- gene human disorders such as failing genes coding normally for the adenosine deaminase, LDL receptor, glucocerebrosidase, blood clotting factor VIII, phenylalanine hydroxydase, dystrophin and others.
- the efficiency of the gene therapy approach has no more to be proved.
- somatic gene transfer approach can now be applied also both to cure and prevent an infectious diseases by releasing in the organ, or in the organism, a protein which is lethal and absolutely specific for the targeted microorganism and without any affinity or effect for the animal.
- Such proteins or peptides having a high and specific antimicrobial activity are divided into two families, one including the bacteriocins and the other the lanthionines, also called lantibiotics.
- the appli ⁇ cation of biotechnology to animal treatment, particu ⁇ larly farm animals, is opening up new avenues of pre- vention and control that will have important implica ⁇ tions.
- the bacteriocins consist of enzymes and other bactericidal proteins. They act as catalysts and are very specific to a single chemical reaction. Bacte ⁇ riocins kill targeted organisms rapidly by lysing the cell wall, and they do not require that the organism undergo cell division. They are produced naturally by bacteria as a means of population control.
- pro ⁇ teins are larger molecules than antibiotics and are expected to persist in the treated organ longer.
- One of these well known bacteriocins is lysostaphin, which is produced by Staphylococcus simulans biovar staphylolyticus .
- lysostaphin is produced by Staphylococcus simulans biovar staphylolyticus .
- the rapid action of bacteriocins reduces the likelihood of an induced resistance in target and non-target organisms. For example, current research conducted so far seems to indicate that bacteriocins used for mastitis treatment are non-toxic to other organisms.
- Lantibiotics are peptide-derived antibiotics with high antimicrobial activity against several patho- genie bacteria.
- the ribosomal origin of lantibiotics was first shown by the isolation of the structural gene, epiA, for epidermin, a lantibiotic produced by Staphylococcus epidermidis .
- the general structure of lantibiotic genes is the same in all lantibiotics described so far.
- the primary transcript of linear lantibiotics is a prepeptide which consists of an N-terminal leader sequence that is followed by the C-terminal propeptide from which the lantibiotic is matured and a characteristic proteolytic processing site with proline at position -2.
- Nisin, produced by several Lactococcus lactis strains is a prominent mem ⁇ ber of the group of lanthionines.
- bacteriocins and lanthionines are ambi- cins, defensins, cecropins, thionins, mellitins, magainins, attacines, diphterins, saponins, cacrutins, xenopins, subtilins, epidermins, pep5, lacticin 481, ancovenins, duramycins, gallidermins, cinnamycins, andropins and mastoparans.
- Another new class of molecule complexes which can be secreted by the transgene, i.e. the genetic con ⁇ struct used for a gene therapy application is the immu- noadhesins.
- the therapeutic potential of antibodies has long been recognized Human antibodies should be minimally immunogenic to the patient; they should therefore be safe for chronic or repeated use. How ⁇ ever, it can be difficult to generate useful human antibodies for several reasons: it is ethically impos ⁇ sible to immunize human beings for experimental pur ⁇ poses, thus the available human antibodies are limited to the products of inadvertent immunization or vaccina ⁇ tion. Furthermore, there have been technical difficul ⁇ ties in the immortalization of human cell lines. Per ⁇ haps the most refractory technical problem is that many applications require antibodies to human antigens; since human antibodies with the desired specificity.
- One approach is to engineer the desired specificity of binding into human antibody variable(V) regions. This can be done by deriving the complementary determining regions either from mouse antibodies, or from in vi tro recombination combined with selection (e.g. combinatorial libraries and phage display technology).
- An alternative approach which sometimes has advantages, is to create an antibody-like molecule by combining a binding site, derived from a human protein such as a cell-surface receptor or cell- adhesion molecule, with antibody constant domains. Such molecules are known as immunoadhesins.
- Immunoadhesins can possess many of the desired chemical and biological properties of antibodies. Examples exist of immunoadhesins that can bind to Fc receptors, mediate antibody-dependent cellular cytotox- icity, and show active transport across the primate placenta. Since the immunoadhesin is constructed from a receptor sequence linked to an appropriate hinge and Fc sequence, the binding specificity of interest can be achieved using entirely human components. Another potential foreign sequence is that in the joining region. One of .well studied immunoadhesins is CD4-IgG which as been found entirely non-immunogenic in human clinical trials.
- a second candidate for clinical use is a rumor necrosis factor receptor immunoadhesin (THFR-IgG); this molecule is particularly interesting, since the soluble receptor itself is found naturally in the body and has been considered as a possible thera ⁇ Illustrative. While soluble receptors are valid clinical candidates, the IgG fusion form may well confer advan ⁇ tages such as longer half-life and improved avidity and affinity. Some receptors or immunoinducers that have been joined to the Fc part of IgG to form immunoadhes ⁇ ins are reported in the literature: T cell receptor, CD4, 1-selectin, CD44, CD28, B7, CTLA-4, CD22;, TNF receptor, NP receptor, IgE receptor, INF- ⁇ receptor.
- immunoadhesins should be useful in antigen recog ⁇ nition, reception to HIV, lymphocyte adhesion, receptor for hyluronidase, interaction B and T lymphocytes, inflammation, septic shock, homeostasis and allergy.
- an immunoadhesin which could has two specific activities.
- an immunoadhesin composed of a lytic enzyme, like the lysostaphin linked to the Fc part of the human IgG which has a high affinity for the protein A at the surface of the bacteria.
- the gene therapy treatments can be applied in such a way that the gene included in the constructs transferred could be coding for an immunomodulator, such as interleukins, chemokines, interferons, leu- kotriens, and certain growth factors.
- an immunomodulator such as interleukins, chemokines, interferons, leu- kotriens, and certain growth factors.
- the immunomodulators can makes the animal more resistant to several microorganisms.
- the present invention relates to the animal gene therapy.
- Animal gene therapy means an approach by which a DNA construct involving an inducible or consti ⁇ tutive promoter linked to a gene coding for a curative or protective protein or antisense RNA or peptide which acts against infectious or potentially infectious microorganisms responsible of the diseases.
- Disclosed is a method for expressing a protein or antisense RNA or peptide which directly or indirectly has a therapeu ⁇ tic or prophylactic effects against infectious microor ⁇ ganisms in an animals.
- the invention is useful for producing a heterologous or homologous protein or antisense RNA or peptide which is tethered to a spe ⁇ cific tissue or organ and which can act on a microor ⁇ ganisms infecting the animal.
- the method involves inducing a liquid complex including a genetic construct into a determined tissue of the animal. If desired, the infused genetic construct can be treated with a polycationic compound and/or a lipid to improve the efficiency with which it is taken up by secretory cells of the animals.
- this invention relates to a method of treating mastitis. More particularly, this invention relates to the use of DNA constructs designed to be transcribed in a therapeutic protein after inser- tion into the mammary gland of both lactating or non- lactating animals.
- Bovine, caprine, ovine and porcine mastitis remain some of the most costly diseases in animal agri ⁇ culture. Mastitis represents a significant economic loss to the diary industry, approximately 70 to 80 per ⁇ cent of which can be attributed to a decrease in milk production. Many infective agents have been implicated as causes of mastitis and these are dealt with sepa ⁇ rately as specific entities in cows, sheep, goats and pigs.
- the stimulating molecules which have been administered by intramammary injection, are cytokines, interleukin-l ⁇ ,, interleukin 2, interferon- ⁇ , tumor necrosis factor- ⁇ .
- a gene therapy procedure is desired that allows a gene to be integrated into a tar ⁇ geted tissue, such as mammary gland, and provides for the elimination, by genetic therapy, of the contaminat- ing microorganisms.
- gene therapy of the mastitic gland eliminates all the side effects of other procedures, enabling also an inserted gene to synthe ⁇ size inductively or constitutively in a permanent man ⁇ ner an effective amount of its therapeutic protein, peptide or RNA antisense product. Therefore, this invention allows a much more specific and effective system of infectious diseases treatment than is cur ⁇ rently possible.
- the present invention provides a recombinant DNA which comprises a nucleotide sequence which encodes a protein or polypeptide which is useful in the prophy ⁇ laxis or treatment of mastitis, and at least one regu ⁇ latory control element which allows for expression of said nucleotide sequence in a mammary gland.
- Suitable regulatory control elements include transcription and translation regulatory sequences. Transcription and translation regulatory sequences are those DNA sequences necessary for efficient expression of the product. In general, such regulatory elements can be operably linked to any nucleotide sequence to control the expression of the sequence, the entire unit being referred to as the "expression cassette".
- the invention further provides an expression cassette containing the above-mentioned recombinant DNA.
- An expression cassette will typically contain, in addition to the coding nucleotide sequence, a pro ⁇ moter region, a translation initiation site and a translation termination sequence.
- Unique endonuclease restriction sites may also be included at the end of an expression cassette to allow the cassette to be easily inserted or removed when creating DNA constructs for use in transformations as is known in the art.
- the invention provides a DNA con- struct designed to express a protein or polypeptide which is useful in the prophylaxis or treatment of infectious diseases after insertion into the targetted tissues.
- the DNA construct comprises an inducible or constitutive promoter which is linked to a coding nucleotide sequence or gene and thereby expresses a therapeutic or protective protein which acts against infectious or potentially infectious microorganisms responsible for the diseases of animals.
- such DNA constructs can be admin- istered to both lactating or non-lactating animals for the prophylaxis or treatment or mastitis.
- the invention further provides a method for the prophylaxis or treatment of mastitis which comprises transforma ⁇ tion of mammary gland tissue with a DNA construct as described above.
- Transformation of mammary gland tissue gener ⁇ ally requires that the DNA be physically placed within the host gland.
- Current transformation procedures use a variety of techniques to introduce naked DNA into a cell and these can be used to transform a mammary gland.
- the DNA can be injected directly into glands through the use of syringe.
- high velocity ballistics can be used to propel small DNA associated particles into the gland through an udder's skin incision.
- the DNA can also be introduced into a mammary gland by insertion of other entities which contain DNA. These entities include minicells, cells (e.g. fibro- blasts, adipocytes, epithelial cells, myoepithelial cells, mammary carcinoma cells, kidney cells), liposomes (e.g.
- the invention also provides a cell which has been transformed using a DNA construct as described above.
- Examples of such cells include Mac-T cells. Genetically transformed cells of this type are suitable for reimplantation into a mammary gland to produce the desired proteins or polypeptides.
- the invention provides a liposome which incorporates the above-described DNA construct.
- Introduction of the naked or complexed DNA con ⁇ structs into the mammary gland can be performed by direct injection through a skin incision of the udder or through the teat canal.
- the DNA construct is admin ⁇ istered in the form of a pharmaceutically or veterinary acceptable composition in combination with a suitable carrier or diluent.
- suitable carriers are liquid car ⁇ riers such as water, salts buffered saline or any other physiological solutions.
- the protein or polypeptides produced should be effective prophylaxis or treatment of mastitis.
- proteins or polypeptides include mucolytic proteins such as enzymes, antibiotics, antibodies, cytokines, tumor necrosis factors as well as proteins which can induce an immune response to infective or potentially infective agents and those which activate polymorphonu- clear neutrophils, or macrophages.
- the invention pro ⁇ vides a recombinant DNA sequence which comprises a nucleotide sequence which encodes a lytic protein or antibody under the control of a mammary gland specific promoter, or any ubiquitous or inducible non mammary promoter.
- the invention is particularly applicable for the treatment of farm animals: bovine, caprine, ovine, and porcine, but can concern also lower mammals or lower milk producers: rabbit, camel and bison.
- the invention can also be used in humans to eliminate par ⁇ ticularly most Staphylococci .
- Fig. 1 illustrates examples of DNA constructs in accordance with the present invention.
- Fig. 2 illustrates the rate of synthesis of human growth hormone in milk's sheep after injection of cationic liposome-DNA complex into the mammary gland.
- animal gene therapy of infec ⁇ tious diseases consists in transfecting a targeted tis ⁇ sue with DNA sequences designed to produce molecules which will be relargued into the organ or the organism, this would than protect the animal against the infect- ing or potentially infecting microbial agents.
- mastitis gene therapy of mammals consists of transfecting the mammary glands with DNA sequences designed to produce molecules which will be relargued into the udder, this would than protect the animal against the infecting or potentially infecting microbial agents.
- the targeted tissue can also be transformed with other DNA sequences such as gene transcription and translation regulatory sequences.
- Transcription and translation regulatory sequences are those DNA sequences necessary for efficient expression of the gene product.
- such regulatory elements can be operably linked to any gene to control the gene's expression, the entire unit being referred to as the "expression cassette".
- An expression cassette will typically contain, in addition to the coding sequence, a promoter region, a translation initiation site and a translation termination sequence.
- Unique endonuclease restriction sites may also be included at the ends of an expression cassette to allow the cassette to be eas ⁇ ily inserted or removed when creation DNA constructs.
- Promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs (bp) upstream of the transcription start site. In most instances the TATA box is required for accurate transcription initiation. By convention, the transcription start site is designated +1. Sequences expending in the 5' (upstream) direction are given negative numbers and sequences extending in the 3 * (downstream) direction are given positive numbers. Promoters can be either constitutive or induc- ible.
- a constitutive promoter controls transcription of a gene at a constant rate during the life of a cell, whereas an inducible promoter's activity fluctuates as determined by the presence (or absence) of a specific inducer.
- the regulatory elements of an inducible pro- moter are usually located further upstream of the tran ⁇ scription start site than the TATA box.
- an inducible promoter should possess each of the following properties: a low to non- existent basal level of expression in the absence of inducer, a high level of expression in the presence of inducer, and an induction scheme that does not other ⁇ wise alter the physiology of the cells.
- the basal transcription activity of all promoters can be increased by the presence of "enhancer" sequences.
- Constitutive promoters can activate the tran ⁇ scription of its linked gene in a tissue specific man ⁇ ner, such as those naturally actives in the epithelial cells of a mammary gland.
- strong consti- tutive promoters are those controlling the expression of caseins, lactoglobulins, lactoferrin, lactalbumin, lysosymes, whey acidic proteins (WAP) coding genes in mammary glands.
- WAP whey acidic proteins
- the promoters origi ⁇ nates from domestic animals, bovine, caprine, ovine or porcine species.
- specific mammary gland promoters can originates from smaller animals, lagomor- phes, rodents, felines or canines.
- CMV Cytomegalovirus
- SV40 Simian virus 40
- MMTV mouse mammary tumor virus
- Inducible promoters include any promoter capa- ble of increasing the amount of gene product produced, by a given gene, in response to exposure to an inducer. Inducible promoters are known to those familiar with the art and a variety exist that could conceivably be used to drive expression of the protective or curative molecule's gene.
- HST heat shock promoter
- glucocorticoid system Promoters regulated by heat shock, such as the promoter normally associated with the gene encoding the 70 kDa heat shock protein, can increase expression several- fold after exposure to elevated temperatures.
- the heat shock promoter could be used as an environmentally inducible promoter for controlling transcription of the protective or curative molecule's gene.
- the glucocor- ticoid system also functions well in triggering the expression of genes including protective or curative molecule's gene.
- the system consists of a gene encod ⁇ ing glucocorticoid receptor protein (GR) which in the presence of a steroid hormone forms a complex with the hormones.
- GR glucocorticoid receptor protein
- the glucocorticoid response element can be included in the DNA transformation construct as a means to induce protective or curative molecule's expression. Once the constructs have been inserted the systemic steroid hormone or glucocorticoid will associate with the constitutively produced GR protein to bind to the GRE elements, thus stimulating expression of the pro- tective or curative molecule's genes (e.g. antibodies or enzymes) .
- the targeted tissue will allow the inserted gene (naked, liposome, cell-enclosed or coated solid particle) to produce its protein product in an amount sufficient to produce the desired effect.
- the inserted gene's products must cure or protect the organ or the organism in which it is expressed against infec ⁇ tious or potentially infectious microorganisms respon ⁇ sible or potentially responsible of the disease.
- the transformation of an animal tissue requires that the DNA be physically placed within the host ani ⁇ mal.
- Current transformation procedures utilize a vari ⁇ ety of techniques to introduce naked DNA into a cell, that can be used to transformed a targeted tissue. In one form of transformation, the DNA is injected directly into the tissue though the use of syringe.
- high velocity ballistics can be used to propel small DNA associated particles into the tissue through a skin's incision.
- the DNA can also be introduced into a targeted tissue by insertion of other entities which contain DNA.
- these entities include minicells, cells (e.g. fibroblasts, adipocytes, Mac-T cells, myoepithelial cells, mammary carcinoma cells, kidney cells, liver cells, lung cells, lympho- cytes, leukocytes), liposomes (e.g. natural or syn ⁇ thetic lipid vehicles, cationic liposomes) or other fusible lipid-surfaced bodies.
- the invention is concerned when a neutralizing, lytic or opsonic molecules are synthesized from the gene used for the infectious disease's gene therapy.
- the gene coding for a mucolytic protein e.g. bacteriocins and lanthionins
- the gene products can serve as an immunomodulator and to induce an immu- nologic response, the activation of polymorphonuclear neutrophils, or macrophages for example.
- the product can be a cytosin or other immunomodulator.
- the genes can be used for in-situ synthesis of the following therapeutic polypeptides: 1. Enzymes or mucolytic proteins, such as lysostaphin and mucolysins;
- Antibodies such as anti-hemolysins, anti-leu- cocidin, anti-protein A, anti-collagen, anti- fibronectin binding protein, anti-laminim, anti- ⁇ -toxin and anti- ⁇ -toxin antibodies; opsonic antibodies and antibodies raised against cell fusion viral protein;
- Cytokines interleukines, chemokines, growth factors
- antibiotics are not very suitable, it can be alternatively used with inducible promoters.
- Microorganisms which can be responsible of the mastitis and be eliminated by the gene therapy approach are:
- Torulopsis spp. In sheep: Pasteurella haemolytica, Staph . Aureus, ActinoBacillus lignieresi , E. coli , Str. uberis and Str. agalactiae, and Cor. pseu- dotuberculosis. In goats: Str. agalactiae, Str. dysgalactiae, Str. pyogenes, and Staph . aureus . In pigs: Aerobacter aerogenes, E. coli , Klebsiella spp. , Pseudomonas aeruginosa, coagulase- positive Staphylococci , Str. agalactiae,
- Str. dysgalactiae and Str. uberis .
- horses Corynebacterium pseudotuberculosis, Str. zooepidemicus, and Str. egui .
- Other microorganisms and diseases which can be eliminated from exotic animals by the method of gene therapy are those causing: In primate: oliomylltis, Measles, Mumps, Rubella, DPT,
- infectious diseases which could be cured or prevented by the application of gene therapy are: anemia, arthritis, rhinotracheitis, bronchitis, bulbar paralysis, bursal diseases, hepatitis, cloaci- tis, coryza, enterohepatitis, hemopoietic necrosis, jaundice, keratoconjunctivitis, laryngotracheitis, myxomatosis, necrotic hepatitis, ophthalmia, pancreatic necrosis, pododernatitis, polyarthritis, pustular balanoposthitis, vulvovaginitis, serositis, sinusitis, stomatitis, synovitis, thromboembolic meningitis, and tracheobronchitis.
- the present invention concerns a gene therapy approach with both curative and prophylactic activities on causing diseases infectious microorganisms.
- the invention concerns in particular DNA sequences, expres ⁇ sion vectors, DNA carriers (lyposome, solid particles) and cells allowing to make use of the process.
- the invention concerns equally the cells (e.g. Mac-T, lung, kidney, muscle cells) genetically trans ⁇ formed in vitro with the gene of interest and reim- planted into the originating tissues to produce the curative or prophylactic proteins, peptide or antisense RNA against microorganisms responsible or potentially responsible of the diseases.
- cells e.g. Mac-T, lung, kidney, muscle cells
- the invention concerns more particularly domes ⁇ tic animals: bovine, caprine, ovine, porcine, feline, canine and birds, but can concerns also more exotic animals such as rabbit, camel and bison.
- the present invention will be more readily un ⁇ derstood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
- Mammary-gland promoters have been used in transgenic animals to limit transgene expression to the mammary gland. Gene therapy techniques to target just one organ for introduction of a foreign gene have also been demonstrated. Most efforts toward postnatal gene therapy have relied on new genetic information into tissues: target cells are removed from the body, infected with viral vectors carrying the new genetic information, and then reimplanted into the body. For some applications, direct introduction of genes into tissues in vivo, with or without the use of viral vec ⁇ tors, would be useful.
- Plasmid pCR3 (InVitrogen) was used as mammalian expression vector. After PCR amplification, the human growth hormone (hGH) cDNA was inserted into pCR3. This resulted in plasmid construct pCR3. Plasmid-Lipofect- AMINETM (BRL) mixture was prepared as described by the manufacturer (GibcoBRL). Briefly, 50 ug of pCR3-hGH suspended in 500 ⁇ l sterile phosphate buffered saline (PBS), was mixed to 100 ⁇ l of LipofectAMINETM also pre ⁇ viously diluted into 500 ⁇ l of PBS, and kept at room temperature at 1 hour.
- PBS sterile phosphate buffered saline
- the circular pCR3-hGH plasmid-LipofectAMINETM mixture was loaded into a glass syringe. Just after dropping, by using a 20-gauge needle, the DNA-liposome complex was infused directly through the udder's skin into the mammary parenchyma. One ml was injected into the right quarter of two ewes. The milk of the left glands was used as negative controls.
- the amount of hGH was measured by immunoassay (Immunocorp) after deter- mining that the milk did not affect the accuracy of the assay. Aliquots (100 ul) of milk samples were ana ⁇ lyzed.
- RESULTS hGH synthesized by injecting pCR3-hGH into the mammary gland was detected all along the lactating period, meaning about 60 days, as illustrated in Fig. 2.
- the concentration of hGH in the sheep's milk was relatively high during the first 5 days. At that time it was of 300 to 400 ng/ml ( ⁇ 43 ng/ml).
- hGH con ⁇ centrations in the milk from the left (control) gland was from 10 to 15 ng/ml for the two sheep everyday of the experiment. No important differences of concentra ⁇ tion of hGH in milk samples were found between each ewes.
- hGH Human growth hormone
- GaLV Gibbon ape leu- kemia virus
- DMEM Dulbecco's modified Eagle's medium
- a construct carrying the JR-gal neo- was transfected into the ecotropic packaging cell line ⁇ Cre by particle bombardment at 1 ⁇ g of DNA per mg of gold beads. Two days after bombardment, the supernatant was removed from these cells and centrifuged, and after the addi- tion of Polybrene at 4 ⁇ g/ml, the retroviral solution was used to infect both amphotropic and GaLV pseudotype packaging cell lines.
- a plasmid carrying the retrovirus vector, MFG-hGH was cotransfected with pSV2neo at a ratio of 50:1 via particle bombardment into PA317s and PG13/LN c ⁇ s.
- Packaging cells producing retrovirus containing the hGH gene were selected by
- the PG13/LN c8 clones that yielded the highest levels of hGH produced from the target cell lines were chosen for the infusions into a goat's mammary glands. Each clone was passed three times into 200 100 mm-plates. Cellular supernatant was collected over a 3-day period, concentrated, and resuspended in DMDM with Gentamycin.
- Polybrene was added to concentrated PG13/LN c8 MFG-hGH viral stock at 80 ⁇ g/ml and loaded into a syr- inge.
- the retrovi ⁇ ruses were infused up the right mammary teat on days 3, 5, 7, 9, 11, and 13 of the hormonal regimen for goats 1, 2, and 4 and goat 3 received infusions on days 3, 5, 7, 9, 10, and 13.
- the amount of viral solution was different for each animal, ranging from 8 to 20 ml, and was determined by the integral capacity of the gland.
- the left gland served as the intraanimal control and was infused with DMEM containing gentamycin.
- Retrovi ⁇ ral stock used for the infusions was then assayed on several cell lines.
- the concentration of hGH in the medium removed from Mac-T and MDBK cells 2 days after infection with retrovirus packaged by PG13/LN c ⁇ clone 6 was 192 and 3.8 ng/ml, respectively. Twenty-eight days after infection, hGH levels from these cells were 119.3 and 4.5 ng/ml, indicating that the provirus LTR was still functioning 4 weeks after infection.
- Viral stock infused on day 13 for goats 1 and 2 was found to contain hGH at 224 ng/ml, indication that the PG13/LN c8 packaging cell were also producing hGH.
- Lactation commenced on day 14 of the hormonal regimen, 24 hr after the last viral infusion. Milk appeared normal throughout the lactations. The volume of milk obtained from each udder half was approximately 150 ml on the first day of lactation for goats 1 and 2 but only 10 ml for goat 3, and 35 ml for goat 4. Milk volume produced by each gland for all four goats increased daily. The levels of hGH were determined by immunoassay with unique hGH secretion patterns for each animal.
- Goat 4 in which prostaglandin E2 was infused at the end of the remaining 19-day lactation after a decline on the first 2 days.
- goat 4 was still secreting hGH at 5 ng/ml after 28 days.
- hGH con ⁇ centrations in the milk from the left (control) gland ranged from 0.0 to 0.6 ng/ml for the four goats at all evaluated times. These numbers are at the detection level of the assay and correlate with ones measured in two other lactating goats that had no exposure to retrovirus.
- the total production of hGH in the four animals ranged from 0.3 to 2 ug/day.
- Lysostaphin is an endopeptidase produced by
- Staphylococcus simulans hydrolyzes the pentaglycine links of the peptidoglycan of members of the genus Staphylococcus and consequently has little activity against other prokaryotes and none against eukaryotes.
- the lysostaphin gene has been cloned and expressed suc ⁇ cessfully in Escherichia coli and Bacillus species (Heath et al., 1987, FEMS Microbiology Letters, 44:129; Heinrich et al., 1987, Molecular and General Genetics, 209:563; Recsei et al., 1987, PNAS USA, 84:1127).
- lysostaphin to promote lysis of Staphylococcus aureus in a variety of experimental situations is well known but the progress made in cloning and expressing the gene in other hosts raises the possibilities of producing large quantities of the enzyme relatively inexpensively. This may permit its use in vivo in new approaches to the control of staphylococcal mastitis, an economically important disease of lactating rumi- nants (Bramley et al., 1990, Res . Vet . Sci . , 49:120). This experiment shows the use of a mastitis model in the lactating mouse and clearly demonstrates potent antibacterial activity of lysostaphin against S. aureus in vivo. Lysostaphin (Sigma Chem.
- mice After a further 30 minutes the mice were killed and the mammary glands were aseptically removed and homogenized in saline containing 0.1 mg/ml trypsin (Sigma Chem.) to destroy active lysostaphin. Ten fold dilutions were placed on 7 per cent calf blood agar (Oxoid Blood Agar Base Number 2), incubated at 37°C overnight and viable counts determined. In a fur- ther experiment using 20 mice a prophylactic use of lysostaphin was simulated by infusing 10 ug of lysostaphin intramammarily, followed either immediately or after one hour by 10- cfu of S. aureus . Control glands were infused with saline instead of lysostaphin. After 24 hours the mice were killed and dissected. Gross pathological changes were noted an viable S. aureus counts determined as described above.
- control glands were darker and reddened, had a brittle texture and some areas of liquefaction and haemolysis. Histological sections revealed a severe inflammation, infiltration of neutrophils and macro- phages with areas of coagulative necrosis. Large num ⁇ bers of Staphylococci were visible. In contrast, the lysostaphin treated glands remained pale and elastic with only slight reddening around the base of the teat. Histological examination showed little or no cellular infiltration, a well preserved and functioning alveolar structure and few cocci .
- S. aureus (Newbould 305) was eliminated from glands of guinea pigs 48 hrs post-infection by 125 ⁇ g of lysostaphin in 14/16, 25 ⁇ g in 5/8, 5 ⁇ g in 5/10, 1 ⁇ g in 0/1, and 0 ⁇ g in 0/3.
- Glands infected with S. aureus at 48 hours post-challenge in untreated guinea pigs persisted, however, 3/25 control glands of treated guinea pigs cleared in response to treatment of the adjacent gland.
- Somatic cell/ml in guinea pig shifted from 10 ⁇ pre-infected glands to cell counts greater than 3 x 10 ⁇ following S. aureus inoculation.
- Treatment with lysostaphin caused a neutrophilic shift in the treated gland to levels exceeding 108 accompanied by an increase in the adjacent non-treated gland but dropped sharply to pre-treatment level.
- the greatest response in control glands was observed in animals receiving 125 ug which corresponded to 2/25 clearance of S. aureus in control glands.
- the leukocyte response to intramammary treat ⁇ ment in the cow is similar to the guinea pig model described above. Somatic cell levels increased ten ⁇ fold in S. aureus infected glands at the milking fol- lowing treatment. Cell levels returned to pre-treat ⁇ ment levels or lower in subsequent milking. A rise in leukocytes alone could not account for clearance of the infection.
- a recombinant mucolytic protein, lysostaphin was evaluated as a potential intramammary therapeutic for Staphylococcus aureus mastitis in dairy cattle.
- Lysostaphin a product of Staphylococcus simulans, enzymatically degrades the cell wall of Straphylococcus aureus and is bactericidal. Thirty Holstein-Friesian dairy cattle in their first lactation were infected with Staphylococcus aureus (Newbould 305, ATCC 29740) in all quarters.
- Infections were established and monitored for somatic cell counts and Staphylococcus aureus colony-forming units 3 weeks prior to subsequent treatment.
- Infected animals were injected through the teat canal with a single dose of recombinant lysostaphin (rLYS) (dose 1 to 500 mg) or after three successive p.m. milking with 100 mg of rLYS in 60 ml of sterile phosphate-buffered saline. Animals were considered cured if the milk remained free of Staphylococcus aureus for a total of 28 milkings after the last treatment.
- rLYS recombinant lysostaphin
- penicillin G retained less than 10% of its bacteriostatic activity over the same incubation time.
- a titration was per ⁇ formed in which a single dose of rLYS at concentrations of 0, 1, 10, 100, or 500 mg was administered. Untreated quarters and the 1-mg treatment failed to clear all quarters of S. aureus . The 10- 100- and 500- mg does transiently cleared the milk of S. aureus for at least one milking. In relapsed quarters, the length of time of the milk remained clear of S. aureus was approximately proportional to the dose administered. Fourteen days after treatment, two quarters were cured with the 100 mg dose and one with the 500 mg dose.
- rLYS maintains a minimal bactericidal concentration (MBC) for approximately 24 h and the experimental infections undergo a 2- to 4- days cycling, multiple infusions of 100 mg of rLYS over three consecutive milking were determined to be optimal to maintain a minimal effective dose for 3 to 5 days and to elicit cures.
- Staphylococcus aureus is one of the primary etiologic agents of bovine mastitis and a major cause of economic loss to the dairy industry.
- An effective mastitis therapy for the lactating dairy cow remains a major unfilled need. Because current therapy is only moderately efficacious and is costly because of milk discard and culling infected animals, treatment only during the dry period has been the adopted herd manage- ment practice of choice. Neither approach addresses the majority of the infections in a lactating animal, which are chronic and subclinical in nature.
- a recom ⁇ binant protein such as rLYS with bactericidal activity against S. aureus could be an extremely useful thera- Pigic to the veterinarian.
- rLYS was as efficacious as antibiotics, natural proteolysis and inactivation in the milk of rLYS, as well as inactivation during inges- tion by the consumer, would potentially minimize any concerns associated with residues in milk.
- the in vivo does titration suggested that the minimal effective therapeutic dose was 100 mg of rLYS.
- the in vivo bactericidal activity of rLYS was most effectively demonstrated by the fact that 95% of the quarters cleared the milk of detectable S. aureus for a minimum of one milking after the last intramammary infusion.
- the model expression plasmid con ⁇ tained the human growth hormone (hGH) gene driven by the human cytomegalovirus immediate early gene 1 pro- moter/enhancer region (CMV). Expression from the naked plasmid DNA jet-injector into lactating mammary glands of sheep was sufficient to be detected by Northern blot analysis when tissue was obtained 48 hours after in vivo transfection.
- hGH human growth hormone
- CMV human cytomegalovirus immediate early gene 1 pro- moter/enhancer region
- the ability to tran- siently transfect lactating mammary tissue in vivo cir ⁇ cumvents the difficulties encountered with in vivo cul ⁇ ture techniques and provides a method for examining mammary regulatory elements and testing of fusion gene constructs designed for the production of transgenic animal bioreactors.
- the lysostaphin gene was introduced into 293 cells (human fetal kidney cells) maintained in vitro.
- the recombinant bacteriocin, the lysostaphin, was secreted in the medium culture and was found to kill contaminant S. aureus during the challenge.
- the lysostaphin gene was obtained by PCR ampli ⁇ fication from extracted DNA of Staphylococcus simulans biovar staphylolyticus (NRRL B-2628), and
- Staphylococcus aureus strain Newbould was used for the challenge in transfected eukaryotic cells. Staphylococcal strains were grown in Brain Heart Infusion (BHI) medium.
- BHI Brain Heart Infusion
- Staphylococcus simulans biovar staphylolyticus was cultured overnight in a stirring incubator at 37°C. The media was centrifuged, and the pellet was resus- pended in 5 ml of 50 mM EDTA-50mM Tris-HCL (pH 7.8) containing 50 mg of lysostaphin (Sigma) ml -1 and the suspension was incubated at 37°C for 2 hours. Purified bacterial DNA was directly amplified by PCR method to isolated the lysostaphin gene.
- the set of oligonucleo- tide primers used were as followed: 5'-TTAAGGTTGAAGAAAACAATT-3' (SEQ ID N0:1) and 5'-GCGCTCACTTTATAGTTCCCCAA-3 ' (SEQ ID NO:2) .
- the amplification was performed by using a Thermal DNA cycler and 2.5 units of Taq DNA polymerase (Perkin Elmer Cetus), and a 30 cycles program with an annealing step at 60°C for 30 sec, elongation at 72°C for 90 sec. and denaturation at 93°C for 10 sec.
- the PCR product was composed by the entire lysostaphin sequence, including the coding gene with the aminoterminal pre- and pro- regions.
- the lysostaphin was linked to an eukaryotic expression vector including the human cytomegalovirus immediate early gene 1 promoter/enhancer region (CMV) and the human interleukin-2 signal peptide.
- CMV human cytomegalovirus immediate early gene 1 promoter/enhancer region
- 293 cells a human foetal kidney cell line transformed by an origin-defective mutant of simian virus 40, were cultured in Dulbecco's modified Eagle medium (Sigma) supplemented with 10% (vol/vol) fetal calf serum (Gibco BRL) and glutamine (1.4 mM) .
- the cells were seeded into 30-mm wells at 500 000 cells par well and grown in 2 ml of medium for 24h at 37°C (in air atmosphere containing 5% CO2) to yield 50 to 60% introduced into the cells by the calcium phosphate method with the following modifications.
- the precipi ⁇ tate containing 7.5 ⁇ g of DNA was added to 2 ml of cul ⁇ ture medium. After 24 h, the medium was replaced with 2 ml of medium per well, and samples of the medium were harvested at each 24 h following transfection to evalu ⁇ ate the production of the lysostaphin by Western blot analysis and ELISA
- the wells containing the transfected 293 cells were infected with 10 2 or 10- ⁇ of Staphylococcus aureus Newbould. Samples of lOO ⁇ l of the infected medium were spreaded on sheep blood agar. After incubation for 24 h at 37°C, the number of colony forming units (CFU) was evaluated to assess the inhibition effect of the recom ⁇ binant lysostaphin on the growth of the bacteria.
- CFU colony forming units
- the modified lysostaphin gene was transfected into tissue culture cells to demonstrate the expres- sion, processing and activity of the enzyme on infect ⁇ ing bacteria. After analysis of the culture medium, a band of approximately 25 kDa was generated; this band was similar in size to mature lysostaphin. The same result was observed in other experiments in which the expression of recombinant lysostaphin has been carried out in eukaryotic cells.
- the ELISA assays have revealed that the recombinant lysostaphin was produced in concentrations of 100 to 250 ng/ml/24h depending of the clone. Activity of the lysostaphin secreted by mammalian cells
- the activity of the recombinant lysostaphin secreted by transfected mammalian cells has been observed by its efficiency to reduce or in some repli- cates to inhibit the growth of infecting Staphylococcus aureus in the culture media.
- Samples of media taken from non-transfected cells have shown none inhibitory effect on the development of the bacteria present in the wells.
- the plates of agar were completely conflu- ent after overnight incubation.
- very few CFU were counted on the plates.
- Less than 100 CFU were observed in our assays when 10 ⁇ bacteria were used, while we did not observed the presence of CFU on gels when 10 2 bac ⁇ teria were added to the wells containing the trans ⁇ fected cells.
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- SEQUENCE DESCRIPTION SEQ ID NO: 1: TTAAGGTTGA AGAAAACAAT T 21
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- SEQUENCE DESCRIPTION SEQ ID NO: 2: GCGCTCACTT TATAGTTCCC CAA 23
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to DNA sequences, expression cassettes and DNA constructs for use in therapy, specifically in gene therapy for the treatment of infectious diseases such as mastitis. Also included are pharmaceutical and veterinary compositions containing the constructs, and cells which have been transformed with the DNA and which are suitable for implantation into a host mammal. The gene therapy of infectious diseases can be effected in situ in targeted tissue or systemically.
Description
ANIMAL GENE THERAPY
BACKGROUND OF THE INVENTION
(a) Field of the Invention The invention relates to DNA sequences, expres¬ sion cassettes and DNA constructs for use in therapy, specifically in gene therapy for the treatment of infectious diseases such as mastitis. Also included are pharmaceutical and veterinary compositions containing the constructs, and cells which have been transformed with the DNA and which are suitable for implantation into a host mammal.
(b) Description of Prior Art
At the highest level, transgenic animals are the principal way to confer transmissible resistance to diseases in animals. Only few years after the first successful gene transfer into mice the new technique was used in farm animals. Several genetic treats have been targeted for the application of transgenesis in domestic animals, but one of those important aspects is the improvement of animal health and disease resistance by gene transfer means. Transient as well as stable genetic improvement leading to disease resistance and treatment achieved by recently developed techniques in molecular biology may contribute considerably to reduce the problem of diseases.
Resistance to infections in animals elicited at various levels. Constitutional and phagocytic mecha¬ nisms (innate immunity) serve as a first line of defense. If these are ineffective the infected organ¬ ism can respond by means of specific (acquired) immu¬ nity. Thus, candidates for gene therapy applications include all genes known to modulate non-specific and specific host defense mechanisms, i.e. cytokines, major histocompatibility complex (MHC) proteins, T-cell receptors (TCR) and proteins conferring specific dis-
ease resistance. Increased protection against patho¬ gens can be conferred also by other strategies such as "intracellular immunization", genetic immunization, antisense sequences as anti-pathogenic agents and dis- ruption of disease susceptibility genes.
Gene modulating Immune Responses
Cytokine orchestrate immune responses through their role as soluble mediators of cell communication. Initially identified to direct viability, prolifera¬ tion, differentiation and homing of leukocytes, they were also found to regulate the production of function or one another. In addition, cytokines interact with, and are produced by cells other than leukocytes, thus providing a means of communication between the immune system and other tissues and organs. Cytokines repre¬ sent a rapidly growing number of regulatory peptide factors including growth factors, interleukins, chemokines, colony-stimulating factors and interferons. Their functions are mediated through binding to cell surface receptors on their target cells. Cytokines have been shown to contribute directly to the develop¬ ment of pathology during infectious diseases and tumorigenesis. Different cytokines have been reported to both positively and negatively influence host defense mechanisms.
Interferon (IFNs) are a well characterized class of cytokines eliciting antiviral and antiprolif- erative activity as well as modulating cell growth, differentiation and immune responses. As well as their more characterized antiviral activity, IFNs are instru¬ mental in counteracting non-viral pathogens mostly through their effects on macrophage activation. The proteins known to be involved in the antiviral and bac- tericidal actions of interferon and their inhibitory mechanisms are numerous. The potency of IFNs to posi-
tively influence host susceptibility to viral infec¬ tions was tested in transgenic mice and cell lines. Transgenic organisms overexpressing IFN-β gene con¬ structs were shown to exhibit enhanced viral resis- tance.
Recent progress in the understanding of signal transduction pathways and transcription factors acti¬ vated by IFNs and a variety of other cytokines promises to open up new therapeutic approaches as well as novel strategies of gene transfer treatments aiming at the improvement of the immune response; i.e. the transfer of cytokine encoding genes per se of distinct "cytokine-specific" signaling components. Constitutive expression of an interferon-stimulated gene factor (ISGF2) also termed interferon regulatory factor (IRF- 1) transgenes has been reported to result in IFN-inde- pendent activation of various IFN-inducible genes and enhanced resistance to viral infection.
Specific Disease Resistance Genes
Other improvement which can be brought to ani¬ mals by local gene transfer is specific disease resis¬ tance. A well examined specific disease resistance gene is the Mxl gene product of certain mouse strains. The mouse Mxl protein belongs to a family of polypeptides with GTPase activity synthesized in IFN-treated verte¬ brate cells. Some Mx proteins have been shown to block the multiplication of certain negative-stranded RNA viruses, as for example Influenza virus , VSV, rhado virus and Thogoto virus. Synthesis of mouse Mxl pro¬ tein in various cell lines and transgenic mice demon¬ strated that it is both necessary and sufficient to promote resistance to influenza A viruses in previously susceptible cells and animals. The cloning and func- tional characterization of this specific disease resis¬ tance gene enabled a gene transfer program to study
whether Mxl transgenic pigs would show reduced suscep¬ tibility to influenza infections.
Natural resistance of certain inbred mouse strains to infection with antigenetically unrelated microorganisms such as Mycobacteria , Salmonellae and Leishmania is controlled by a dominant locus on chromo¬ some 1 called Beg, Lsh or Ity respectively. The locus affects the capacity of the host to restrict prolifera¬ tion of these infectious pathogens during the non-spe- cific macrophage-dependent phase of infection. A posi¬ tional cloning approach resulted in the isolation of a candidate Beg gene designated Nramp. The reduction of susceptibility to Salmonella infections by transgenesis or gene therapy ( in vivo or ex vivo) means is of great value for animal production, especially poultry. Large difference in resistance to Salmonella in chicken inbred lines have been observed. Furthermore, natural resistance or susceptibility to infection with Mycobacteria in humans and Brucella in cattle has been shown to be under genetic control similar to that observed in inbred mice and governed by Beg. Chronic infection of cattle with Brucella abortus causes the spontaneous abortion of fetal calves, threatening the economic well-being of the dairy and beef industries. Genetic resistance to certain retroviruses has been observed as a polymorphic trait in several experi¬ mental species. One of the identified loci in mice, Fv-4 , resembles the 3' half of a murine leukemia virus extending from the end of the pol gene through a com- plete env gene. Expression of Fv-4 encoding only the viral envelope protein in transgenic mice conferred resistance to infection with ecotropic retroviruses. The mechanism of Fv-4 resistance is thought to be related to the phenomenon of viral interference, i.e. competition of the synthesized envelope protein with
exogenous virus for the virus receptor. Similar mecha¬ nisms are used in antiviral strategies known as "intracellular immunization".
Expression of a transgene encoding an immu- noglobulin specific for a common pathogen can provide immunity for that pathogen. As shown by many investi¬ gations, cloned genes coding for monoclonal antibodies can be expressed in large amounts in genetically manipulated mice. These mice produce antibodies against specific antigens without prior contact or immunization.
Intracellular Immunization
The concept of "intracellular immunization" essentially involves overexpression in the host of an aberrant form (dominant-negative mutant) of a viral protein that is able to interfere strongly with the replication of the wild type virus. Elegant studies in cultured cells resulting in acquired resistance to various viruses include strategies preventing virus attachment to the target cells, blocking the formation of virus-host transcription complexes, expressing domi- nant-negative viral trans-activators or interfering with the assembly of infectious viral particles. Endogenous mouse mammary tumor virus (MMTV) proviruses have been found to co-segregate genetically with loci termed self-superantigens identical to a pro¬ tein encoded in the long terminal repeat of MMTV. Genetically manipulated mice expressing high levels of this self-superantigen were shown to be protected from viral infection by deletion of a specific class of T- cells which is the target for infection.
The definition of "intracellular immunization" is also applied for antiviral strategies described in different connections such as expression of specific
resistance genes, antisense RNAs or other antiviral components.
Recently, an "intracellular immunization" approach carried out in farm animals was reported. Transgenic sheep were produced and were shown express¬ ing the visna virus envelope ( env) gene. The visna virus belongs to a subfamily of ovine retroviruses that cause encephalitis, pneumonia and arthritis in sheep. The env glycoprotein is responsible for the binding of this virus to host cells. The target cell for visna virus replication in infected sheep is the macrophage. The expression of env protein on the cell surface of visna-infected cells induces immune responses to the virus. Expression of a gene construct consisting of the visna U3 enhancer region fused to the env gene in transgenic sheep had no obvious deleterious effect. Thus, the genetically manipulated sheep lines provide an evidence for the potential of a retroviral env gly¬ coprotein to prevent infection and/or to modulate dis- ease in its natural host after virus challenge.
Antisense RNA
The use of antisense RNA to inhibit RNA func¬ tion within cells or whole organisms has provided a valuable molecular biological method. Antisense RNA functions by binding in a highly specific manner to complementary sequences, thereby blocking the ability of the bound RNA to be processed and/or translated. Antisense sequences are considered an attractive alter- native to conventional drugs in the therapy of micro- bial infections, cancer, autoimmune diseases and other malfunctions. Gene transfer experiments with antisense constructs have been carried out in mice and rabbits. Genetically manipulated mice expressing antisense RNA targeted to the retroviral packaging sequences of Molony murine leukemia virus did not develop leukemia
following challenge with infectious viruses. Trans¬ genic rabbits expressing an antisense construct comple¬ mentary to adenovirus h5 RNA were produced. Primary cells from these rabbits were found to be 90-98% more resistant to adenovirus infection than cells from con¬ trol animals.
The use of antisense RNAs as anti-parasitho- genic agents can be developed to result not only in RNA-RNA hybrids but catallytically cleave a phosphodi- ester bound in the target RNA strand. Four structural motifs (hammerhead and hairpin first identified in plant RNA pathogens, the delta motif found in human hepatitis delta virus and a less well characterized motif from Neuspora ) have thus far been described as intermediates in these self-cleavage reactions. By flanking the hammerhead motif of this ribozyme family with antisense sequences, the cleavage of specific tar¬ get RNAs has been demonstrated. A large number of sub¬ strate molecules can be processed by the catalytic RNA because the ribozyme per se is not consumed during the cleavage reaction. Bovine leukemia virus (BLV), a retrovirus , causes persistent lymphocytosis and B-lym- phocyte lymphoma in cattle and sheep. A hammerhead ribozyme flanked by antisense sequences directed against regulatory proteins of BLV was shown to inhibit BLV expression in persistently infected cells. This demonstrates the possibility of generating localized ( in vivo or ex vivo) or generalized (transgenic ani¬ mals) gene therapies that will be resistant to BLV- induced diseases.
Somatic Gene Transfer Approaches
Somatic gene transfer into farm animals will become more significant. Ex vivo and more recently in vivo gene therapy has been applied for several genetic diseases in human. Current therapies developed for
— o —
more than 10 gene human disorders, such as failing genes coding normally for the adenosine deaminase, LDL receptor, glucocerebrosidase, blood clotting factor VIII, phenylalanine hydroxydase, dystrophin and others. The efficiency of the gene therapy approach has no more to be proved.
Novel methods for gene transfer into somatic cells promise to be highly efficient. These include viral vectors for delivering gene constructs and non- viral technologies, such as micro-bombarding or injec¬ tion of DNA particles or solutions into tissues or blood vessels. Although most efforts are directed pri¬ marily towards the possibility of treating human dis¬ eases, some applications of somatic gene transfer could be of great value in veterinary medicine. It makes direct "genetic immunization" and other methods of immunomodulation possible. "Genetic immunization", i.e. application of DNA constructs encoding immunogens, has at least two powerful uses. One is to simplify the procedure and to shorten the time required to produce antibodies to particular proteins by eliminating the steps for protein purification. it would be more rapid again to introduce a gene encoding directly a neutral¬ izing or bacteriocid antibody in the organism. The second is the genetic vaccination of animals against infections by producing foreign antisense encoded by appropriate gene construct.
The somatic gene transfer approach can now be applied also both to cure and prevent an infectious diseases by releasing in the organ, or in the organism, a protein which is lethal and absolutely specific for the targeted microorganism and without any affinity or effect for the animal.
Such proteins or peptides having a high and specific antimicrobial activity are divided into two
families, one including the bacteriocins and the other the lanthionines, also called lantibiotics. The appli¬ cation of biotechnology to animal treatment, particu¬ larly farm animals, is opening up new avenues of pre- vention and control that will have important implica¬ tions. The bacteriocins consist of enzymes and other bactericidal proteins. They act as catalysts and are very specific to a single chemical reaction. Bacte¬ riocins kill targeted organisms rapidly by lysing the cell wall, and they do not require that the organism undergo cell division. They are produced naturally by bacteria as a means of population control. These pro¬ teins are larger molecules than antibiotics and are expected to persist in the treated organ longer. One of these well known bacteriocins is lysostaphin, which is produced by Staphylococcus simulans biovar staphylolyticus . Unlike antibiotics, the rapid action of bacteriocins reduces the likelihood of an induced resistance in target and non-target organisms. For example, current research conducted so far seems to indicate that bacteriocins used for mastitis treatment are non-toxic to other organisms.
Lantibiotics are peptide-derived antibiotics with high antimicrobial activity against several patho- genie bacteria. The ribosomal origin of lantibiotics was first shown by the isolation of the structural gene, epiA, for epidermin, a lantibiotic produced by Staphylococcus epidermidis . The general structure of lantibiotic genes is the same in all lantibiotics described so far. The primary transcript of linear lantibiotics is a prepeptide which consists of an N-terminal leader sequence that is followed by the C-terminal propeptide from which the lantibiotic is matured and a characteristic proteolytic processing site with proline at position -2. Nisin, produced by
several Lactococcus lactis strains, is a prominent mem¬ ber of the group of lanthionines.
Other bacteriocins and lanthionines are ambi- cins, defensins, cecropins, thionins, mellitins, magainins, attacines, diphterins, saponins, cacrutins, xenopins, subtilins, epidermins, pep5, lacticin 481, ancovenins, duramycins, gallidermins, cinnamycins, andropins and mastoparans.
Another new class of molecule complexes which can be secreted by the transgene, i.e. the genetic con¬ struct used for a gene therapy application is the immu- noadhesins. The therapeutic potential of antibodies has long been recognized Human antibodies should be minimally immunogenic to the patient; they should therefore be safe for chronic or repeated use. How¬ ever, it can be difficult to generate useful human antibodies for several reasons: it is ethically impos¬ sible to immunize human beings for experimental pur¬ poses, thus the available human antibodies are limited to the products of inadvertent immunization or vaccina¬ tion. Furthermore, there have been technical difficul¬ ties in the immortalization of human cell lines. Per¬ haps the most refractory technical problem is that many applications require antibodies to human antigens; since human antibodies with the desired specificity.
Several potential approaches exist to circum¬ venting these problems. One approach is to engineer the desired specificity of binding into human antibody variable(V) regions. This can be done by deriving the complementary determining regions either from mouse antibodies, or from in vi tro recombination combined with selection (e.g. combinatorial libraries and phage display technology). An alternative approach, which sometimes has advantages, is to create an antibody-like molecule by combining a binding site, derived from a
human protein such as a cell-surface receptor or cell- adhesion molecule, with antibody constant domains. Such molecules are known as immunoadhesins.
Immunoadhesins can possess many of the desired chemical and biological properties of antibodies. Examples exist of immunoadhesins that can bind to Fc receptors, mediate antibody-dependent cellular cytotox- icity, and show active transport across the primate placenta. Since the immunoadhesin is constructed from a receptor sequence linked to an appropriate hinge and Fc sequence, the binding specificity of interest can be achieved using entirely human components. Another potential foreign sequence is that in the joining region. One of .well studied immunoadhesins is CD4-IgG which as been found entirely non-immunogenic in human clinical trials. A second candidate for clinical use is a rumor necrosis factor receptor immunoadhesin (THFR-IgG); this molecule is particularly interesting, since the soluble receptor itself is found naturally in the body and has been considered as a possible thera¬ peutic. While soluble receptors are valid clinical candidates, the IgG fusion form may well confer advan¬ tages such as longer half-life and improved avidity and affinity. Some receptors or immunoinducers that have been joined to the Fc part of IgG to form immunoadhes¬ ins are reported in the literature: T cell receptor, CD4, 1-selectin, CD44, CD28, B7, CTLA-4, CD22;, TNF receptor, NP receptor, IgE receptor, INF-γ receptor. These immunoadhesins should be useful in antigen recog¬ nition, reception to HIV, lymphocyte adhesion, receptor for hyluronidase, interaction B and T lymphocytes, inflammation, septic shock, homeostasis and allergy.
In animals, the advent of molecular biology techniques allow to create an immunoadhesin which could
has two specific activities. For example, in the goal to eliminate a contamination with Staphylococcus aureus it can be possible to have an immunoadhesin composed of a lytic enzyme, like the lysostaphin, linked to the Fc part of the human IgG which has a high affinity for the protein A at the surface of the bacteria. Once the Fc is linked to the protein A on Staphylococcus aureus, the lytic part, the lysostaphin, can lyse the bacteria. The gene therapy treatments can be applied in such a way that the gene included in the constructs transferred could be coding for an immunomodulator, such as interleukins, chemokines, interferons, leu- kotriens, and certain growth factors. As explained before, the immunomodulators can makes the animal more resistant to several microorganisms.
SUMMARY OF THE INVENTION
The present invention relates to the animal gene therapy. Animal gene therapy means an approach by which a DNA construct involving an inducible or consti¬ tutive promoter linked to a gene coding for a curative or protective protein or antisense RNA or peptide which acts against infectious or potentially infectious microorganisms responsible of the diseases. Disclosed is a method for expressing a protein or antisense RNA or peptide which directly or indirectly has a therapeu¬ tic or prophylactic effects against infectious microor¬ ganisms in an animals. The invention is useful for producing a heterologous or homologous protein or antisense RNA or peptide which is tethered to a spe¬ cific tissue or organ and which can act on a microor¬ ganisms infecting the animal. The method involves inducing a liquid complex including a genetic construct into a determined tissue of the animal. If desired, the infused genetic construct can be treated with a
polycationic compound and/or a lipid to improve the efficiency with which it is taken up by secretory cells of the animals.
The most costly infectious disease in animals is mastitis caused by the infection of the mammary gland. Among others, this invention relates to a method of treating mastitis. More particularly, this invention relates to the use of DNA constructs designed to be transcribed in a therapeutic protein after inser- tion into the mammary gland of both lactating or non- lactating animals.
Bovine, caprine, ovine and porcine mastitis remain some of the most costly diseases in animal agri¬ culture. Mastitis represents a significant economic loss to the diary industry, approximately 70 to 80 per¬ cent of which can be attributed to a decrease in milk production. Many infective agents have been implicated as causes of mastitis and these are dealt with sepa¬ rately as specific entities in cows, sheep, goats and pigs.
Despite significant progress in mastitis con¬ trol due to widespread adoption of post-milking teat antiseptisis, many herds continue to be plagued by this disease. A variety of different procedures have been described and used to cure mastitis caused by bacteria and yeast. These procedures include the systemic immu¬ nization of the infected animals with whole or partial protein extracts of the infective agents in order to stimulate the immune response of the treated animal to these agents. Antibodies generally produced in this way act against a membrane protein, a binding protein or a toxin secreted by the microorganisms. Hence these antibodies act as anti-adhesive, anti-toxin, neutraliz¬ ing or opsonic molecules (Nordhaug et al., 1994, J Dairy Sci . , 77:1267 & 1276). Nevertheless, the blood-
milk barrier prevents all but a very small proportion of circulation IgG antibodies from reaching mammary secretion during lactation.
Other procedures have been carried out in order to stimulate the diapedesis and phagocytosis of con¬ taminating agents by leukocytes, more particularly polymorphonuclear neutrophils and macrophages. The stimulating molecules, which have been administered by intramammary injection, are cytokines, interleukin-lβ,, interleukin 2, interferon-γ, tumor necrosis factor-α.
The most widely used procedure to cure infec¬ tious diseases is administration of antibiotics. How¬ ever, this approach inflicts a lot of side effects to the animal and particularly in the case of dairy ani- mals, the milk must be discarded during the treatment period. Unfortunately, all current procedures are very short-lasting and consequently relatively inefficient. For example, none of the gram positive bacteria are entirely eliminated from the udder after treatments with antibiotics.
For these reasons a gene therapy procedure is desired that allows a gene to be integrated into a tar¬ geted tissue, such as mammary gland, and provides for the elimination, by genetic therapy, of the contaminat- ing microorganisms. In addition, gene therapy of the mastitic gland eliminates all the side effects of other procedures, enabling also an inserted gene to synthe¬ size inductively or constitutively in a permanent man¬ ner an effective amount of its therapeutic protein, peptide or RNA antisense product. Therefore, this invention allows a much more specific and effective system of infectious diseases treatment than is cur¬ rently possible.
Additional objects, features, and advantages of the invention will become apparent to those skilled in
the art upon consideration of the following detailed description of preferred embodiments exemplifying the best mode of the invention as presently perceived.
The present invention provides a recombinant DNA which comprises a nucleotide sequence which encodes a protein or polypeptide which is useful in the prophy¬ laxis or treatment of mastitis, and at least one regu¬ latory control element which allows for expression of said nucleotide sequence in a mammary gland. Suitable regulatory control elements include transcription and translation regulatory sequences. Transcription and translation regulatory sequences are those DNA sequences necessary for efficient expression of the product. In general, such regulatory elements can be operably linked to any nucleotide sequence to control the expression of the sequence, the entire unit being referred to as the "expression cassette". Hence the invention further provides an expression cassette containing the above-mentioned recombinant DNA. An expression cassette will typically contain, in addition to the coding nucleotide sequence, a pro¬ moter region, a translation initiation site and a translation termination sequence.
Unique endonuclease restriction sites may also be included at the end of an expression cassette to allow the cassette to be easily inserted or removed when creating DNA constructs for use in transformations as is known in the art.
In particular the invention provides a DNA con- struct designed to express a protein or polypeptide which is useful in the prophylaxis or treatment of infectious diseases after insertion into the targetted tissues. Suitably the DNA construct comprises an inducible or constitutive promoter which is linked to a coding nucleotide sequence or gene and thereby
expresses a therapeutic or protective protein which acts against infectious or potentially infectious microorganisms responsible for the diseases of animals. For example, such DNA constructs can be admin- istered to both lactating or non-lactating animals for the prophylaxis or treatment or mastitis. Hence the invention further provides a method for the prophylaxis or treatment of mastitis which comprises transforma¬ tion of mammary gland tissue with a DNA construct as described above.
The present applicants have found that expres¬ sion of proteins in mammary glands over an extended time period is possible and that a gene therapy approach to the problem of mastitis is feasible. Inte- gration of a gene which encodes a therapeutic protein or polypeptide into mammary gland tissue would allow, for example, for the elimination of infective microor¬ ganisms by genetic therapy. In addition, gene therapy of the mastitis gland eliminates all side effects of other procedures, also enabling an inserted gene to synthesize permanently and inductively or constitu- tively an effective amount of its therapeutic protein product. A gene therapy approach would be a much more specific and effective system of mastitis treatment than is currently available.
Transformation of mammary gland tissue gener¬ ally requires that the DNA be physically placed within the host gland. Current transformation procedures use a variety of techniques to introduce naked DNA into a cell and these can be used to transform a mammary gland. For example, the DNA can be injected directly into glands through the use of syringe. Alternatively, high velocity ballistics can be used to propel small DNA associated particles into the gland through an udder's skin incision.
The DNA can also be introduced into a mammary gland by insertion of other entities which contain DNA. These entities include minicells, cells (e.g. fibro- blasts, adipocytes, epithelial cells, myoepithelial cells, mammary carcinoma cells, kidney cells), liposomes (e.g. natural or synthetic lipid vehicles, cationic liposomes) or other fusible lipid-surfaced bodies. The entities are transformed in vitro prior to insertion using the above-described DNA constructs. Thus the invention also provides a cell which has been transformed using a DNA construct as described above. Examples of such cells include Mac-T cells. Genetically transformed cells of this type are suitable for reimplantation into a mammary gland to produce the desired proteins or polypeptides.
Furthermore the invention provides a liposome which incorporates the above-described DNA construct.
Introduction of the naked or complexed DNA con¬ structs into the mammary gland can be performed by direct injection through a skin incision of the udder or through the teat canal.
Where appropriate, the DNA construct is admin¬ istered in the form of a pharmaceutically or veterinary acceptable composition in combination with a suitable carrier or diluent. Suitable carriers are liquid car¬ riers such as water, salts buffered saline or any other physiological solutions. These compositions form a further aspect of the invention.
The protein or polypeptides produced should be effective prophylaxis or treatment of mastitis. Such proteins or polypeptides include mucolytic proteins such as enzymes, antibiotics, antibodies, cytokines, tumor necrosis factors as well as proteins which can induce an immune response to infective or potentially
infective agents and those which activate polymorphonu- clear neutrophils, or macrophages.
In a preferred embodiment, the invention pro¬ vides a recombinant DNA sequence which comprises a nucleotide sequence which encodes a lytic protein or antibody under the control of a mammary gland specific promoter, or any ubiquitous or inducible non mammary promoter.
The invention is particularly applicable for the treatment of farm animals: bovine, caprine, ovine, and porcine, but can concern also lower mammals or lower milk producers: rabbit, camel and bison. The invention can also be used in humans to eliminate par¬ ticularly most Staphylococci .
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 illustrates examples of DNA constructs in accordance with the present invention; and
Fig. 2 illustrates the rate of synthesis of human growth hormone in milk's sheep after injection of cationic liposome-DNA complex into the mammary gland.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with one preferred embodiment of the present invention, animal gene therapy of infec¬ tious diseases consists in transfecting a targeted tis¬ sue with DNA sequences designed to produce molecules which will be relargued into the organ or the organism, this would than protect the animal against the infect- ing or potentially infecting microbial agents.
In accordance with another embodiment of the present invention, mastitis gene therapy of mammals consists of transfecting the mammary glands with DNA sequences designed to produce molecules which will be relargued into the udder, this would than protect the
animal against the infecting or potentially infecting microbial agents.
The targeted tissue can also be transformed with other DNA sequences such as gene transcription and translation regulatory sequences. Transcription and translation regulatory sequences are those DNA sequences necessary for efficient expression of the gene product. In general such regulatory elements can be operably linked to any gene to control the gene's expression, the entire unit being referred to as the "expression cassette". An expression cassette will typically contain, in addition to the coding sequence, a promoter region, a translation initiation site and a translation termination sequence. Unique endonuclease restriction sites may also be included at the ends of an expression cassette to allow the cassette to be eas¬ ily inserted or removed when creation DNA constructs.
The expression of a gene is primarily directed by its own promoter, although other DNA regulatory ele- ments are necessary for efficient expression of a gene product. Promoter sequence elements include the TATA box consensus sequence (TATAAT), which is usually 20 to 30 base pairs (bp) upstream of the transcription start site. In most instances the TATA box is required for accurate transcription initiation. By convention, the transcription start site is designated +1. Sequences expending in the 5' (upstream) direction are given negative numbers and sequences extending in the 3 * (downstream) direction are given positive numbers. Promoters can be either constitutive or induc- ible. A constitutive promoter controls transcription of a gene at a constant rate during the life of a cell, whereas an inducible promoter's activity fluctuates as determined by the presence (or absence) of a specific inducer. The regulatory elements of an inducible pro-
moter are usually located further upstream of the tran¬ scription start site than the TATA box. Ideally, for experimental purposes, an inducible promoter should possess each of the following properties: a low to non- existent basal level of expression in the absence of inducer, a high level of expression in the presence of inducer, and an induction scheme that does not other¬ wise alter the physiology of the cells. The basal transcription activity of all promoters can be increased by the presence of "enhancer" sequences. Although the mechanism is unclear, certain defined enhancer regulatory sequences are known, to those familiar with the art, to increase a promoter's tran¬ scription rate when the sequence is brought in proxim- ity to the promoter.
Constitutive promoters can activate the tran¬ scription of its linked gene in a tissue specific man¬ ner, such as those naturally actives in the epithelial cells of a mammary gland. For example, strong consti- tutive promoters are those controlling the expression of caseins, lactoglobulins, lactoferrin, lactalbumin, lysosymes, whey acidic proteins (WAP) coding genes in mammary glands. Preferentially, the promoters origi¬ nates from domestic animals, bovine, caprine, ovine or porcine species. Alternatively, specific mammary gland promoters can originates from smaller animals, lagomor- phes, rodents, felines or canines. Other constitutive promoters regulating expression of the cytoplasmic β- actin or ubiquitin genes can be used. Viral or retroviral promoters can be used also, like Cytomegalovirus (CMV), Simian virus 40 (SV40) or mouse mammary tumor virus (MMTV, which is additionally inducible) .
Inducible promoters include any promoter capa- ble of increasing the amount of gene product produced,
by a given gene, in response to exposure to an inducer. Inducible promoters are known to those familiar with the art and a variety exist that could conceivably be used to drive expression of the protective or curative molecule's gene.
Two preferred inducible promoters are the heat shock promoter (HST) and the glucocorticoid system. Promoters regulated by heat shock, such as the promoter normally associated with the gene encoding the 70 kDa heat shock protein, can increase expression several- fold after exposure to elevated temperatures. The heat shock promoter could be used as an environmentally inducible promoter for controlling transcription of the protective or curative molecule's gene. The glucocor- ticoid system also functions well in triggering the expression of genes including protective or curative molecule's gene. The system consists of a gene encod¬ ing glucocorticoid receptor protein (GR) which in the presence of a steroid hormone forms a complex with the hormones. This complex then binds to a short nucleo¬ tide sequence (26 bp) named the glucocorticoid response element (GRE), and this binding activates the expres¬ sion of linked genes. The glucocorticoid system can be included in the DNA transformation construct as a means to induce protective or curative molecule's expression. Once the constructs have been inserted the systemic steroid hormone or glucocorticoid will associate with the constitutively produced GR protein to bind to the GRE elements, thus stimulating expression of the pro- tective or curative molecule's genes (e.g. antibodies or enzymes) .
Presumably the targeted tissue will allow the inserted gene (naked, liposome, cell-enclosed or coated solid particle) to produce its protein product in an amount sufficient to produce the desired effect. The
inserted gene's products must cure or protect the organ or the organism in which it is expressed against infec¬ tious or potentially infectious microorganisms respon¬ sible or potentially responsible of the disease. The transformation of an animal tissue requires that the DNA be physically placed within the host ani¬ mal. Current transformation procedures utilize a vari¬ ety of techniques to introduce naked DNA into a cell, that can be used to transformed a targeted tissue. In one form of transformation, the DNA is injected directly into the tissue though the use of syringe. Alternatively, high velocity ballistics can be used to propel small DNA associated particles into the tissue through a skin's incision. In other forms, the DNA can also be introduced into a targeted tissue by insertion of other entities which contain DNA. These entities include minicells, cells (e.g. fibroblasts, adipocytes, Mac-T cells, myoepithelial cells, mammary carcinoma cells, kidney cells, liver cells, lung cells, lympho- cytes, leukocytes), liposomes (e.g. natural or syn¬ thetic lipid vehicles, cationic liposomes) or other fusible lipid-surfaced bodies.
The invention is concerned when a neutralizing, lytic or opsonic molecules are synthesized from the gene used for the infectious disease's gene therapy. Preferentially, in the case of the mastitis, the gene coding for a mucolytic protein (e.g. bacteriocins and lanthionins) can be used to eliminates the Gram posi¬ tive bacteria (mostly cocci ) . The gene products can serve as an immunomodulator and to induce an immu- nologic response, the activation of polymorphonuclear neutrophils, or macrophages for example. The product can be a cytosin or other immunomodulator. Alterna¬ tively, the genes can be used for in-situ synthesis of the following therapeutic polypeptides:
1. Enzymes or mucolytic proteins, such as lysostaphin and mucolysins;
2. Antibodies, such as anti-hemolysins, anti-leu- cocidin, anti-protein A, anti-collagen, anti- fibronectin binding protein, anti-laminim, anti-α-toxin and anti-β-toxin antibodies; opsonic antibodies and antibodies raised against cell fusion viral protein;
3. Cytokines, interleukines, chemokines, growth factors;
4. Interferons;
5. Tumor necrosis factors; and
6. Immunoadhesins or immunotoxins.
While antibiotics are not very suitable, it can be alternatively used with inducible promoters.
Microorganisms which can be responsible of the mastitis and be eliminated by the gene therapy approach are:
In cattle Streptococcus agalactiae, Str. ube, Str. zooepidemicus, Str. dysgalactiae, Str. fae- calis and Str. pneumoniae, Straphylococcus aureus, Escherichia coli , Klebsiella spp. , Corynebacterium pyogenes , Cor. bovis, Myco- bacterium tuberculosis, Mycobacterium spp. , Bacillus cereus, Pasteurella multocida,
Pseudomonas pyocyaneus, Sphaerophorus necrophorus, Serratia marcescens, Myco- plasma spp. , Nocardia spp. , a fungus Trichosoporon spp. , yeasts Candida sp. , Cryptococcus neoformans, Saccharomyces, and
Torulopsis spp. . In sheep: Pasteurella haemolytica, Staph . Aureus, ActinoBacillus lignieresi , E. coli , Str. uberis and Str. agalactiae, and Cor. pseu- dotuberculosis.
In goats: Str. agalactiae, Str. dysgalactiae, Str. pyogenes, and Staph . aureus . In pigs: Aerobacter aerogenes, E. coli , Klebsiella spp. , Pseudomonas aeruginosa, coagulase- positive Staphylococci , Str. agalactiae,
Str. dysgalactiae, and Str. uberis . In horses: Corynebacterium pseudotuberculosis, Str. zooepidemicus, and Str. egui . Other microorganisms and diseases which can be eliminated from exotic animals by the method of gene therapy are those causing: In primate: oliomylltis, Measles, Mumps, Rubella, DPT,
Tetanus. In canidae:Can. distemper, Can. adenovirus, Can. par- vovirus, Can. parainfluenza, Rabies, Lepto- spire bacterin. In felidae:Fel. panleukopenia, Fel. rhinotracheitis,
Fel. caliciviruses, Rabies. In Artiodactyla: BVD, 8-way Clos. bacterin, 5-way Lepto. bacterin, Parainfluenza 3,
Prions, Scatters.
Examples of infectious diseases which could be cured or prevented by the application of gene therapy are: anemia, arthritis, rhinotracheitis, bronchitis, bulbar paralysis, bursal diseases, hepatitis, cloaci- tis, coryza, enterohepatitis, hemopoietic necrosis, jaundice, keratoconjunctivitis, laryngotracheitis, myxomatosis, necrotic hepatitis, ophthalmia, pancreatic necrosis, pododernatitis, polyarthritis, pustular balanoposthitis, vulvovaginitis, serositis, sinusitis, stomatitis, synovitis, thromboembolic meningitis, and tracheobronchitis.
The present invention concerns a gene therapy approach with both curative and prophylactic activities on causing diseases infectious microorganisms. The
invention concerns in particular DNA sequences, expres¬ sion vectors, DNA carriers (lyposome, solid particles) and cells allowing to make use of the process.
The invention concerns equally the cells (e.g. Mac-T, lung, kidney, muscle cells) genetically trans¬ formed in vitro with the gene of interest and reim- planted into the originating tissues to produce the curative or prophylactic proteins, peptide or antisense RNA against microorganisms responsible or potentially responsible of the diseases.
The invention concerns more particularly domes¬ tic animals: bovine, caprine, ovine, porcine, feline, canine and birds, but can concerns also more exotic animals such as rabbit, camel and bison. The present invention will be more readily un¬ derstood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.
EXAMPLE I
Long-term persistence of plasmid DNA and foreign expression in sheep mammary glands
Mammary-gland promoters have been used in transgenic animals to limit transgene expression to the mammary gland. Gene therapy techniques to target just one organ for introduction of a foreign gene have also been demonstrated. Most efforts toward postnatal gene therapy have relied on new genetic information into tissues: target cells are removed from the body, infected with viral vectors carrying the new genetic information, and then reimplanted into the body. For some applications, direct introduction of genes into tissues in vivo, with or without the use of viral vec¬ tors, would be useful. Direct in vivo gene transfer into postnatal animals has been achieved with formula¬ tions of DNA encapsulated in liposomes, DNA entrapped
in proteoliposomes containing viral envelope receptor proteins (Nicolau et al., 1983, PNAS USA, 80:1068), calcium phosphate-coprecipitated DNA (Benvenisty et al., 1986, PNAS USA, 83:9551), and DNA coupled to a polylysine-glycoprotein carrier complex (Wu and Wu, 1988, J. Biol . Chem. , 263:14621). In vivo infectivity of cloned viral DNA sequences after direct intrahepatic injection with or without formation of calcium phos¬ phate coprecipitates has also been described (Seeger et al., 2984, PNAS USA, 81:5849). With the use of cat¬ ionic lipid vesicles (Feigner et al., 1989, PNAS USA, 84:7413), mRNA sequences containing elements that enhance stability can be efficiently translated in tis¬ sue culture cells (Malone et al., 1989, PNAS USA, 86:6077) and in Xenopus laevis embryos (Malone, 1989, Focus 11:61). It is demonstrated here that injection of pure DNA complexed to cationic liposomes directly into sheep mammary gland results in significant expres¬ sion of reporter gene within the gland. Preparation of plasmid-liposome mixture
Plasmid pCR3 (InVitrogen) was used as mammalian expression vector. After PCR amplification, the human growth hormone (hGH) cDNA was inserted into pCR3. This resulted in plasmid construct pCR3. Plasmid-Lipofect- AMINE™ (BRL) mixture was prepared as described by the manufacturer (GibcoBRL). Briefly, 50 ug of pCR3-hGH suspended in 500 μl sterile phosphate buffered saline (PBS), was mixed to 100 μl of LipofectAMINE™ also pre¬ viously diluted into 500 μl of PBS, and kept at room temperature at 1 hour.
Infusion of the plasmid-liposome complexes into sheep mammary gland
The circular pCR3-hGH plasmid-LipofectAMINE™ mixture was loaded into a glass syringe. Just after dropping, by using a 20-gauge needle, the DNA-liposome
complex was infused directly through the udder's skin into the mammary parenchyma. One ml was injected into the right quarter of two ewes. The milk of the left glands was used as negative controls.
Analysis of sheep milk
Sheep were milked once daily by hand with the milk kept at -80°C until analyzed. The amount of hGH was measured by immunoassay (Immunocorp) after deter- mining that the milk did not affect the accuracy of the assay. Aliquots (100 ul) of milk samples were ana¬ lyzed.
RESULTS hGH synthesized by injecting pCR3-hGH into the mammary gland was detected all along the lactating period, meaning about 60 days, as illustrated in Fig. 2. The concentration of hGH in the sheep's milk was relatively high during the first 5 days. At that time it was of 300 to 400 ng/ml (± 43 ng/ml). hGH con¬ centrations in the milk from the left (control) gland was from 10 to 15 ng/ml for the two sheep everyday of the experiment. No important differences of concentra¬ tion of hGH in milk samples were found between each ewes.
Conclusion
These results demonstrate that expression from plasmid DNA can persist in a sheep's mammary gland for at least 60 days. The unprecedented ability of plasmid DNA to stably express a foreign gene in a mammary gland throughout the lactating period of a sheep has impor¬ tant implications for gene therapy. The stable expres¬ sion of circular plasmid DNA suggest that foreign acceleration or by viral transduction should also be stably maintained.
EXAMPLE II
Human growth hormone (hGH) secretion in goats1 milk after direct transfer of the hGH gene into the mammary gland
An alternative route of introducing genes into the mammary parenchyma is through expansion of gene therapy techniques. In this study two Gibbon ape leu- kemia virus (GaLV) pseudotype retroviral vectors were used to transfer reporter genes into a goat's mammary secretory epithelial cells in vitro and in vivo.
Cells and tissue culture MDBKs, a bovine kidney cell line and Mac-T cells, a bovine mammary epithelial cell line were used. Retroviral packaging cell lines used (φCre, PA317, and PG13/LNc8) were acquired from ATCC. Cells were main¬ tained in Dulbecco's modified Eagle's medium (DMEM) supplemented with gentamycin (54 mg/ml) and 10% fetal calf serum, 37°C with 5% CO2 /95% air.
Establishment of producer cell lines
A construct carrying the JR-gal neo- (Wang et al., 1991, Cancer Res . , 51:2642) was transfected into the ecotropic packaging cell line φCre by particle bombardment at 1 μg of DNA per mg of gold beads. Two days after bombardment, the supernatant was removed from these cells and centrifuged, and after the addi- tion of Polybrene at 4 μg/ml, the retroviral solution was used to infect both amphotropic and GaLV pseudotype packaging cell lines. A plasmid carrying the retrovirus vector, MFG-hGH was cotransfected with pSV2neo at a ratio of 50:1 via particle bombardment into PA317s and PG13/LN cδs. Packaging cells producing retrovirus containing the hGH gene were selected by
G418 resistance (400 μg/ml).
Virus producing cells
The PG13/LN c8 clones that yielded the highest levels of hGH produced from the target cell lines were chosen for the infusions into a goat's mammary glands. Each clone was passed three times into 200 100 mm-plates. Cellular supernatant was collected over a 3-day period, concentrated, and resuspended in DMDM with Gentamycin.
Induction of cell division and lactation of goats
Two 2-year-old (goats 1 and 2) and two 1-year- old (goats 3 and 4) virgin Saanen-crossbred goats were treated with exogenous steroids i.m. over a 14-day interval to induce mammogenesis and subsequent lacta- tion.
«
Infusion of viral stocks into a goat's mammary glands
Polybrene was added to concentrated PG13/LN c8 MFG-hGH viral stock at 80 μg/ml and loaded into a syr- inge. By using a 22-gauge stub adapter, the retrovi¬ ruses were infused up the right mammary teat on days 3, 5, 7, 9, 11, and 13 of the hormonal regimen for goats 1, 2, and 4 and goat 3 received infusions on days 3, 5, 7, 9, 10, and 13. The amount of viral solution was different for each animal, ranging from 8 to 20 ml, and was determined by the integral capacity of the gland. The left gland served as the intraanimal control and was infused with DMEM containing gentamycin. Retrovi¬ ral stock used for the infusions was then assayed on several cell lines.
Analysis of goat's milk
Goats were milked twice daily by hand with the morning milk kept at -80°C until analyzed. The amount of hGH was measured by immunoassay after determining that the milk did not affect the accuracy of the assay.
Aliquots (5 μl) of milk samples diluted 1:10 in double distilled water were also analyzed by SDS/PAGE on 14% gels stained, with Coomassie blue. The protein concen¬ tration of the milk samples was determined by using BCA (Pierce et al., 1977, Anl . Biochem. , 81:478).
RESULTS
Vector production of packaging cell lines
The concentration of hGH in the medium removed from Mac-T and MDBK cells 2 days after infection with retrovirus packaged by PG13/LN cδ clone 6 was 192 and 3.8 ng/ml, respectively. Twenty-eight days after infection, hGH levels from these cells were 119.3 and 4.5 ng/ml, indicating that the provirus LTR was still functioning 4 weeks after infection.
Infusion of viral stocks into the mammary glands of goats
Viral stock infused on day 13 for goats 1 and 2 was found to contain hGH at 224 ng/ml, indication that the PG13/LN c8 packaging cell were also producing hGH.
Analysis of goat milk
Lactation commenced on day 14 of the hormonal regimen, 24 hr after the last viral infusion. Milk appeared normal throughout the lactations. The volume of milk obtained from each udder half was approximately 150 ml on the first day of lactation for goats 1 and 2 but only 10 ml for goat 3, and 35 ml for goat 4. Milk volume produced by each gland for all four goats increased daily. The levels of hGH were determined by immunoassay with unique hGH secretion patterns for each animal. In goat 1, concentration of hGH dropped stead¬ ily until day 9 of lactation when it leveled at 3-5 ng/ml, whereas goats had a more precipitous decrease in measured hGH from day 1 to day 2 of lactation, though
the animal's production of hGH stabilized at 2-3 ng/ml around day 10. Milking was stopped on day 15 of lacta¬ tion for goats 1 and 2. Levels of hGH in the milk of goat 3 dropped dramatically from day 1 to 2 of lacta- tion and then increased from day 8 to day 9 where it remained at 23 ng/ml until day 16 when it began to fall again. Goat 4, in which prostaglandin E2 was infused at the end of the remaining 19-day lactation after a decline on the first 2 days. In addition, goat 4 was still secreting hGH at 5 ng/ml after 28 days. hGH con¬ centrations in the milk from the left (control) gland ranged from 0.0 to 0.6 ng/ml for the four goats at all evaluated times. These numbers are at the detection level of the assay and correlate with ones measured in two other lactating goats that had no exposure to retrovirus. The total production of hGH in the four animals ranged from 0.3 to 2 ug/day.
If the hGH gene had been stably incorporated into the stem-cell population, it would have been expected that the goats would also secrete hGH in a second lactation after the gland had undergone involu¬ tion. A second lactation was induced in two of the goats, and though goat 1 did not produce hGH, goat 2 began secreting detectable amounts of hGH starting on day 5 from the right (infused) gland and during the subsequent 10 days hGH concentrations varied from 0.4 to 2.3 ng/ml. Milk from the left control gland during this lactation always had no detectable levels of hGH.
SDS/PAGE of goat's milk sampled throughout the period of collection showed no consistent differences in the protein profiles from the retroviral-infused right glands, the control left glands, and a goat not exposed to the retrovirus. Protein concentrations measured by BCA of the milk with hGH were not statisti- cally different from the control milk, thus production
of hGH by the mammary secretory epithelial cells did not appear to affect the normal cellular protein machinery. There was an indication that the milk's proteins in the treated gland were not secreted at maximal concentration on day 1 of lactation.
Conclusion
Applying gene therapy technology and replica¬ tion-defective retroviral vectors to directly introduce a foreign gene into a ruminant mammary gland has dra¬ matically reduced the time of production of pharmaceu¬ ticals in milk, from years to weeks. Although the lev¬ els of expression found are low, the methods might find application in the evaluation of different gene con- structs as a prelude to production of transgenic ani¬ mals or in the production of low levels of important proteins for evaluation purposes.
EXAMPLE III
Effect of lysostaphin on Staphylococcus aureus infec¬ tions on the mouse's mammary gland
Lysostaphin is an endopeptidase produced by
Staphylococcus simulans . It hydrolyzes the pentaglycine links of the peptidoglycan of members of the genus Staphylococcus and consequently has little activity against other prokaryotes and none against eukaryotes. The lysostaphin gene has been cloned and expressed suc¬ cessfully in Escherichia coli and Bacillus species (Heath et al., 1987, FEMS Microbiology Letters, 44:129; Heinrich et al., 1987, Molecular and General Genetics, 209:563; Recsei et al., 1987, PNAS USA, 84:1127). The use of lysostaphin to promote lysis of Staphylococcus aureus in a variety of experimental situations is well known but the progress made in cloning and expressing the gene in other hosts raises the possibilities of
producing large quantities of the enzyme relatively inexpensively. This may permit its use in vivo in new approaches to the control of staphylococcal mastitis, an economically important disease of lactating rumi- nants (Bramley et al., 1990, Res . Vet . Sci . , 49:120). This experiment shows the use of a mastitis model in the lactating mouse and clearly demonstrates potent antibacterial activity of lysostaphin against S. aureus in vivo. Lysostaphin (Sigma Chem. ) was dissolved in skimmed milk (Oxoid) to provide a range of concentra¬ tions between 0.1 and 100 μg/ml. Controls without lysostaphin were included. One ml volumes of the con¬ trols and lysostaphin dilutions were inoculated with 10* colony forming units (cfu) of S. aureus M60. This strain produces both and β toxins and was isolated from a case of bovine mastitis. Lysostaphin concentra¬ tions exceeding 2 to 3 ug/ml in milk produced a 2 to 3 log o reduction in viable S. aureus, whereas 10 ug/ml in milk reduced S. aureus from a mean of 7.95 log ιo/ml in the control to 2.0 logio/ml- Consequently a dose of 10 ug of lysostaphin was selected for use in vivo. Anaesthetized mice, of strain MF1, were inoculated in the upper pair of abdominal mammary glands (designated R4 and L4). Eight lactating mice were inoculated with 10 cfu of S. aureus in 0.1 ml saline in both R4 and L4. This was followed one hour later by the infusion of 10 ug lysostaphin in 0.1 ml saline into R4 and 0.1 ml saline into L4. After a further 30 minutes the mice were killed and the mammary glands were aseptically removed and homogenized in saline containing 0.1 mg/ml trypsin (Sigma Chem.) to destroy active lysostaphin. Ten fold dilutions were placed on 7 per cent calf blood agar (Oxoid Blood Agar Base Number 2), incubated at 37°C overnight and viable counts determined. In a fur-
ther experiment using 20 mice a prophylactic use of lysostaphin was simulated by infusing 10 ug of lysostaphin intramammarily, followed either immediately or after one hour by 10- cfu of S. aureus . Control glands were infused with saline instead of lysostaphin. After 24 hours the mice were killed and dissected. Gross pathological changes were noted an viable S. aureus counts determined as described above.
RESULTS
Infusion with lOmg lysostaphin into mammary glands previously inoculated with S. aureus reduced bacterial recoveries, compared to the controls, by more than 99 per cent in 30 min. This reduction was statis- tically significant (t=2.56; P<0.02). When 10 ug of lysostaphin was administered either immediately or one hour before S. aureus inoculation, recoveries after 24 hours averaged around 102 viable S. aureus per mammary gland compared with approximately 10^ per mammary gland for the saline treated controls. In the latter case, the control glands showed severe pathological changes typical of acute staphylococcal mastitis in the mouse. The control glands were darker and reddened, had a brittle texture and some areas of liquefaction and haemolysis. Histological sections revealed a severe inflammation, infiltration of neutrophils and macro- phages with areas of coagulative necrosis. Large num¬ bers of Staphylococci were visible. In contrast, the lysostaphin treated glands remained pale and elastic with only slight reddening around the base of the teat. Histological examination showed little or no cellular infiltration, a well preserved and functioning alveolar structure and few cocci .
Conclusion
These experiments clearly demonstrate the anti- staphylococcal activity of lysostaphin in vivo. Both a therapeutic and prophylactic potential were demon- strated. The cloning of the lysostaphin gene may make it readily available for therapeutic use at a competi¬ tive price and its relatively high specificity makes it attractive for use in food-producing animals. Further¬ more, advances in transgenic technology allow the direction of the expression of transgenes to the mam¬ mary gland of ruminants (Simons et al., 1987, Nature, 328:530). In general, this has been applied to the production of pharmacologically active substances for use in human medicine. However, the incorporation and expression of the lysostaphin gene in the lactating mammary gland could potentially increase the resistance of the animal to staphylococcal mastitis.
EXAMPLE IV
Lysostaphin efficacy for treatment of Staphylococcus aureus intramammary infection
Cloned-derived lysostaphin was evaluated as to its bactericidal effect on S. aureus intramammary infections. S. aureus (Newbould 305) was eliminated from glands of guinea pigs 48 hrs post-infection by 125 μg of lysostaphin in 14/16, 25 μg in 5/8, 5 μg in 5/10, 1 μg in 0/1, and 0 μg in 0/3. Glands infected with S. aureus at 48 hours post-challenge in untreated guinea pigs persisted, however, 3/25 control glands of treated guinea pigs cleared in response to treatment of the adjacent gland.
Somatic cell/ml in guinea pig shifted from 10^ pre-infected glands to cell counts greater than 3 x 10^ following S. aureus inoculation. Treatment with lysostaphin caused a neutrophilic shift in the treated gland to levels exceeding 108 accompanied by an increase in the adjacent non-treated gland but dropped sharply to pre-treatment level. The greatest response in control glands was observed in animals receiving 125 ug which corresponded to 2/25 clearance of S. aureus in control glands.
The leukocyte response to intramammary treat¬ ment in the cow is similar to the guinea pig model described above. Somatic cell levels increased ten¬ fold in S. aureus infected glands at the milking fol- lowing treatment. Cell levels returned to pre-treat¬ ment levels or lower in subsequent milking. A rise in leukocytes alone could not account for clearance of the infection.
EXAMPLE V
Use of a recombinant bacterial enzyme (Lysostaphin) as a mastitis therapeutic
A recombinant mucolytic protein, lysostaphin, was evaluated as a potential intramammary therapeutic for Staphylococcus aureus mastitis in dairy cattle.
Lysostaphin, a product of Staphylococcus simulans, enzymatically degrades the cell wall of Straphylococcus aureus and is bactericidal. Thirty Holstein-Friesian dairy cattle in their first lactation were infected with Staphylococcus aureus (Newbould 305, ATCC 29740) in all quarters.
Infections were established and monitored for somatic cell counts and Staphylococcus aureus colony-forming units 3 weeks prior to subsequent treatment. Infected animals were injected through the teat canal with a single dose of recombinant lysostaphin (rLYS) (dose 1
to 500 mg) or after three successive p.m. milking with 100 mg of rLYS in 60 ml of sterile phosphate-buffered saline. Animals were considered cured if the milk remained free of Staphylococcus aureus for a total of 28 milkings after the last treatment.
RESULTS
Kinetic analysis of immunologically active rLYS demonstrated that a minimum bactericidal concentration was maintained in the milk for up to 72 hours at 37°C.
In contrast, penicillin G retained less than 10% of its bacteriostatic activity over the same incubation time.
Dose titration and kinetics of rLYS in the bovine mam- mary gland
In order to determine the optimal effective dose to elicit long-term cures, a titration was per¬ formed in which a single dose of rLYS at concentrations of 0, 1, 10, 100, or 500 mg was administered. Untreated quarters and the 1-mg treatment failed to clear all quarters of S. aureus . The 10- 100- and 500- mg does transiently cleared the milk of S. aureus for at least one milking. In relapsed quarters, the length of time of the milk remained clear of S. aureus was approximately proportional to the dose administered. Fourteen days after treatment, two quarters were cured with the 100 mg dose and one with the 500 mg dose. Because rLYS maintains a minimal bactericidal concentration (MBC) for approximately 24 h and the experimental infections undergo a 2- to 4- days cycling, multiple infusions of 100 mg of rLYS over three consecutive milking were determined to be optimal to maintain a minimal effective dose for 3 to 5 days and to elicit cures.
Conclusion
Staphylococcus aureus is one of the primary etiologic agents of bovine mastitis and a major cause of economic loss to the dairy industry. An effective mastitis therapy for the lactating dairy cow remains a major unfilled need. Because current therapy is only moderately efficacious and is costly because of milk discard and culling infected animals, treatment only during the dry period has been the adopted herd manage- ment practice of choice. Neither approach addresses the majority of the infections in a lactating animal, which are chronic and subclinical in nature. A recom¬ binant protein such as rLYS with bactericidal activity against S. aureus could be an extremely useful thera- peutic to the veterinarian. If rLYS was as efficacious as antibiotics, natural proteolysis and inactivation in the milk of rLYS, as well as inactivation during inges- tion by the consumer, would potentially minimize any concerns associated with residues in milk. The in vivo does titration suggested that the minimal effective therapeutic dose was 100 mg of rLYS. However, therapeutically, it would be desirable to administer multiple infusions of rLYS to maintain a minimal bactericidal activity within the milk of treated glands for one to three successive milkings. The in vivo bactericidal activity of rLYS was most effectively demonstrated by the fact that 95% of the quarters cleared the milk of detectable S. aureus for a minimum of one milking after the last intramammary infusion.
EXAMPLE VI
Expression of jet-injected plasmid DNA in the ovine mammary gland A jet-injection based DNA delivery system has been evaluated as a means to transiently transfect the
— 3y —
lactating mammary gland in vivo and as a technique for DNA vaccination. The model expression plasmid con¬ tained the human growth hormone (hGH) gene driven by the human cytomegalovirus immediate early gene 1 pro- moter/enhancer region (CMV). Expression from the naked plasmid DNA jet-injector into lactating mammary glands of sheep was sufficient to be detected by Northern blot analysis when tissue was obtained 48 hours after in vivo transfection. In conclusion, the ability to tran- siently transfect lactating mammary tissue in vivo cir¬ cumvents the difficulties encountered with in vivo cul¬ ture techniques and provides a method for examining mammary regulatory elements and testing of fusion gene constructs designed for the production of transgenic animal bioreactors.
EXAMPLE VII
Elimination of Staphylococcus aureus in an eukaryotic system expressing the lysostaphin
The lysostaphin gene was introduced into 293 cells (human fetal kidney cells) maintained in vitro.
The recombinant bacteriocin, the lysostaphin, was secreted in the medium culture and was found to kill contaminant S. aureus during the challenge.
The lysostaphin gene was obtained by PCR ampli¬ fication from extracted DNA of Staphylococcus simulans biovar staphylolyticus (NRRL B-2628), and
Staphylococcus aureus strain Newbould (ATCC) was used for the challenge in transfected eukaryotic cells. Staphylococcal strains were grown in Brain Heart Infusion (BHI) medium.
Purification of the lysostaphin gene Staphylococcus simulans biovar staphylolyticus was cultured overnight in a stirring incubator at 37°C. The media was centrifuged, and the pellet was resus-
pended in 5 ml of 50 mM EDTA-50mM Tris-HCL (pH 7.8) containing 50 mg of lysostaphin (Sigma) ml-1 and the suspension was incubated at 37°C for 2 hours. Purified bacterial DNA was directly amplified by PCR method to isolated the lysostaphin gene. The set of oligonucleo- tide primers used were as followed: 5'-TTAAGGTTGAAGAAAACAATT-3' (SEQ ID N0:1) and 5'-GCGCTCACTTTATAGTTCCCCAA-3 ' (SEQ ID NO:2) . The amplification was performed by using a Thermal DNA cycler and 2.5 units of Taq DNA polymerase (Perkin Elmer Cetus), and a 30 cycles program with an annealing step at 60°C for 30 sec, elongation at 72°C for 90 sec. and denaturation at 93°C for 10 sec. The PCR product was composed by the entire lysostaphin sequence, including the coding gene with the aminoterminal pre- and pro- regions. All other recombinant DNA procedures, including restriction endonuclease digestion, ligation, washing with phenol- chloroform mixture, ethanol precipitation, transforma- tion and cloning of the constructs in E. coli strain DH5a, were carried out by standard methods. All enzymes were from Boehringer Mannheim.
The lysostaphin was linked to an eukaryotic expression vector including the human cytomegalovirus immediate early gene 1 promoter/enhancer region (CMV) and the human interleukin-2 signal peptide.
Cell culture and DNA transfection
293 cells, a human foetal kidney cell line transformed by an origin-defective mutant of simian virus 40, were cultured in Dulbecco's modified Eagle medium (Sigma) supplemented with 10% (vol/vol) fetal calf serum (Gibco BRL) and glutamine (1.4 mM) . The cells were seeded into 30-mm wells at 500 000 cells par well and grown in 2 ml of medium for 24h at 37°C (in air atmosphere containing 5% CO2) to yield 50 to 60%
introduced into the cells by the calcium phosphate method with the following modifications. The precipi¬ tate containing 7.5 μg of DNA was added to 2 ml of cul¬ ture medium. After 24 h, the medium was replaced with 2 ml of medium per well, and samples of the medium were harvested at each 24 h following transfection to evalu¬ ate the production of the lysostaphin by Western blot analysis and ELISA
Assay for biological active lysostaphin
The wells containing the transfected 293 cells were infected with 102 or 10-^ of Staphylococcus aureus Newbould. Samples of lOOμl of the infected medium were spreaded on sheep blood agar. After incubation for 24 h at 37°C, the number of colony forming units (CFU) was evaluated to assess the inhibition effect of the recom¬ binant lysostaphin on the growth of the bacteria.
RESULTS
Production of recombinant lysostaphin by transfected eukaryotic cells
The modified lysostaphin gene was transfected into tissue culture cells to demonstrate the expres- sion, processing and activity of the enzyme on infect¬ ing bacteria. After analysis of the culture medium, a band of approximately 25 kDa was generated; this band was similar in size to mature lysostaphin. The same result was observed in other experiments in which the expression of recombinant lysostaphin has been carried out in eukaryotic cells. The ELISA assays have revealed that the recombinant lysostaphin was produced in concentrations of 100 to 250 ng/ml/24h depending of the clone.
Activity of the lysostaphin secreted by mammalian cells
The activity of the recombinant lysostaphin secreted by transfected mammalian cells has been observed by its efficiency to reduce or in some repli- cates to inhibit the growth of infecting Staphylococcus aureus in the culture media. Samples of media taken from non-transfected cells have shown none inhibitory effect on the development of the bacteria present in the wells. The plates of agar were completely conflu- ent after overnight incubation. In contrast, when an initial amount of 10^ bacteria was cultured in presence of transfected eukaryotic cells, very few CFU were counted on the plates. Less than 100 CFU were observed in our assays when 10^ bacteria were used, while we did not observed the presence of CFU on gels when 102 bac¬ teria were added to the wells containing the trans¬ fected cells.
While the invention has been described in con¬ nection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any varia¬ tions, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.
SEQUENCE LISTING
(1) GENERJΛL INFORMATION:
(i) APPLICANT:
(A) NAME: IMMUNOVA
(B) STREET: 2750 rue Einstein, Bureau 110
(C) CITY: Sainte-Foy
(D) STATE: Quebec
(E) COUNTRY: Canada
(F) POSTVL CODE (ZIP) : G1P 4R1
(G) TELEPHONE: (418) 654-2240 (H) TELEFAX: (418) 654-2125
(A) NAME: GAGNE, Marc
(B) STREET: 913 rue Pellan
(C) CITY: St-Jean-Chrysostome
(D) STATE: Quebec
(E) COUNTRY: Canada
(F) POSTAL CODE (ZIP) : G6Z 2S8
(ii) TITLE OF INVENTION: ANIMAL GENE THERAPY (iii) NUMBER OF SEQUENCES: 2
(iv) COMPUTER REMABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)
(Vi) PRIOR APPLICATION DATA:
(A) /APPLICATION NUMBER: GB 9509461. 1
(B) FILING DATE: 10-MAY-1995
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TTAAGGTTGA AGAAAACAAT T 21
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRΛNDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: GCGCTCACTT TATAGTTCCC CAA 23
Claims
1. A method of treatment and/or prevention of an infectious disease in an animal, which comprises the steps of: a) producing a recombinant DNA expression system comprising at least a DNA sequence encoding for a therapeutic protein, peptide or antisense RNA operably linked to a promoter capable of directing the in vivo expression of said DNA sequence of a therapeutically effective amount of said protein, peptide or antisense RNA; and b) introducing into the animal the DNA expression system of step a) for expression of said therapeutic protein, peptide or antisense RNA.
2. The method of claim 1, wherein said treatment and/or prevention of the disease is effected in si tu and said DNA expression system is introduced in targeted tissue.
3. The method of claim 1, wherein said DNA expres¬ sion system is transgenic recombinant animal cells.
4. The method of claim 3, wherein said cells are selected from the group consisting of epithelial mam¬ mary gland cells, blood cells, lymphocytes, leukocytes, T-lymphocytes, B-lymphocytes, erythrocytes, muscle cells, hepatic cells, kidney cells, lung cells, secretory cells and non-secretory cells.
5. The method of claim 3, wherein said DNA expres¬ sion system is selected from the group consisting of a lipidic liposome, a cationic liposome, an anionic liposome.
6. The method of claims 1, 2, 3, 4 or 5, wherein said DNA sequence and said promoter are inserted into an expression vector.
7. The method of claim 6, wherein said vector is a viral vector or a retroviral vector.
8. The method of claims 1, 2, 3, 4, 5, 6 or 7, wherein said infectious diseases are caused by bacte¬ ria, virus, retrovirus, parasite, fungi, mold, yeast, prions or scrapies.
9. The method of claim 8, wherein said therapeutic protein, peptide or antisense RNA are selected from the group consisting of bacteriocins, lanthionins, lactoferrin, lysosyme.
10. The method of claim 9, wherein said bacte¬ riocins and/or lanthionins are ambicins, defensins, cecropins, thionins, mellitins, magainins, attacines, diphterins, saponins, cacrutins, xenopins, subtilins, epidermins, pep5, lacticin 481, ancovenins, duramycins, gallidermins or cinnamycins.
11. The method of claim 8, wherein said therapeutic protein, peptide or antisense RNA is selected from the group consisting of immunoglobulins, lactoglobulins, α -lactalbumin, bile-salt-stimulated lipase or ribosyme, cytokines, chemokines, growth factors, immunomodulators and major histocompatibility complex (MHC) proteins.
12. The method of claim 3, which further comprises a 5' and 3' expression regulation DNA sequence and a secretory DNA sequence functional in said animal cells and operably linked to the recombinant DNA encoding said therapeutic protein, peptide or antisense RNA.
13. A non-human transgenic animal for the produc¬ tion of a recombinant protein, peptide or antisense RNA systemically or in targeted tissue, which comprises at least an expression regulation DNA sequence and a secretory DNA sequence encoding a secretory signal sequence operatively linked to a DNA sequence encoding said protein, peptide or antisense RNA for systemic expression or for expression in targeted tissue cells of said animal.
14. The non-human transgenic animal of claim 13, wherein said expression regulation DNA sequence is selected from the group consisting of a constitutive promoter, an inducible promoter, a cytomegalo virus promoter.
15. The non-human transgenic animal of claim 14 wherein said promoter is selected from the group of DNA sequences encoding lactoferrin, serum albumin, αSl- casein, αS2-casein, β-casein, K-casein, α-lactalbumin, whey acidic protein, β-lactoglobulin, cytokines, chemokines and growth factors.
16. The non-human transgenic animal of claim 13, wherein said secretory signal sequence is selected from the group consisting of DNA sequences encoding lactoferrin, serum albumin, αSl-casein, αS2-casein, β- casein, κ-casein, α-lactalbumin, β-lactoglobulin, cytokines, chemokines or growth factors.
17. The non-human transgenic animal of claim 13, wherein the expression regulation and secretory signal sequences are from human, bovine, caprine, ovine, feline, canine, lagomorphes, birds and fishes.
18. The non-human transgenic animal of claim 13, wherein the promoter is tissue-specific for expression in targeted tissue.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9509461 | 1995-05-10 | ||
GBGB9509461.1A GB9509461D0 (en) | 1995-05-10 | 1995-05-10 | DNA molecules and constructs and their use in the treatment of mastitis |
PCT/CA1996/000297 WO1996035793A1 (en) | 1995-05-10 | 1996-05-10 | Animal gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0828839A1 true EP0828839A1 (en) | 1998-03-18 |
Family
ID=10774245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96913403A Withdrawn EP0828839A1 (en) | 1995-05-10 | 1996-05-10 | Animal gene therapy |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0828839A1 (en) |
JP (1) | JPH11505113A (en) |
AU (1) | AU724905B2 (en) |
CA (1) | CA2220472A1 (en) |
GB (1) | GB9509461D0 (en) |
NZ (1) | NZ307139A (en) |
WO (1) | WO1996035793A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114118A (en) * | 1996-09-20 | 2000-09-05 | Texas A&M University System | Method of identification of animals resistant or susceptible to disease such as ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis |
US6156517A (en) * | 1997-01-17 | 2000-12-05 | The Scripps Research Institute | RNA binding protein and binding site useful for expression of recombinant molecules |
JP2001511363A (en) | 1997-07-22 | 2001-08-14 | ノビムーヌ ソシエテ アノニム | Method for diagnosing and treating autoimmune diseases such as insulin-dependent diabetes mellitus containing retroviral superantigen |
CA2211293A1 (en) * | 1997-07-23 | 1999-01-23 | Immunova Ltee | Recombinant lysostaphin analogs |
US6875903B2 (en) | 1998-06-22 | 2005-04-05 | University Of Vermont | Treatment of Staphylococcus infections |
US7091332B1 (en) | 1998-06-22 | 2006-08-15 | University Of Vermont | Treatment of staphylococcus infections |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0279582A3 (en) * | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
WO1993025567A1 (en) * | 1992-06-15 | 1993-12-23 | Gene Pharming Europe B.V. | Production of recombinant polypeptides by bovine species and transgenic methods |
PH30997A (en) * | 1990-03-12 | 1997-12-23 | Ciba Geigy | Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes. |
DK0532650T3 (en) * | 1990-05-25 | 1996-10-07 | Univ Washington | Process for triggering plant protection mechanisms |
-
1995
- 1995-05-10 GB GBGB9509461.1A patent/GB9509461D0/en active Pending
-
1996
- 1996-05-10 JP JP8533627A patent/JPH11505113A/en active Pending
- 1996-05-10 EP EP96913403A patent/EP0828839A1/en not_active Withdrawn
- 1996-05-10 AU AU56416/96A patent/AU724905B2/en not_active Ceased
- 1996-05-10 WO PCT/CA1996/000297 patent/WO1996035793A1/en not_active Application Discontinuation
- 1996-05-10 CA CA002220472A patent/CA2220472A1/en not_active Abandoned
- 1996-05-10 NZ NZ307139A patent/NZ307139A/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO9635793A1 * |
Also Published As
Publication number | Publication date |
---|---|
CA2220472A1 (en) | 1996-11-14 |
JPH11505113A (en) | 1999-05-18 |
GB9509461D0 (en) | 1995-07-05 |
AU724905B2 (en) | 2000-10-05 |
AU5641696A (en) | 1996-11-29 |
WO1996035793A1 (en) | 1996-11-14 |
NZ307139A (en) | 1999-08-30 |
MX9708615A (en) | 1998-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5571697A (en) | Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus | |
KR100288749B1 (en) | Isolated nucleic acid molecule encoding the tumor rejection antigen precursor MAGE-3 and its use | |
US5780009A (en) | Direct gene transfer into the ruminant mammary gland | |
CA2184810A1 (en) | Product and process for t cell regulation | |
WO2006076288A2 (en) | Dna constructs for long-term expression of intravascularly injected naked dna | |
JP2000513209A (en) | Antimicrobial peptides and methods of use | |
JP2002514887A (en) | Method of secreting thrombopoietin polypeptide | |
Zhang et al. | Mammary gland expression of antibacterial peptide genes to inhibit bacterial pathogens causing mastitis | |
JP2002512006A (en) | Therapeutic application of mature FLINT (mFLINT) polypeptide or OPG3 that is a member of the TNF receptor superfamily | |
AU724905B2 (en) | Animal gene therapy | |
AU8328598A (en) | Recombinant lysostaphin analogs | |
Kolb | Engineering immunity in the mammary gland | |
MXPA97008615A (en) | Genes therapy anima | |
WO2021079536A1 (en) | Bacteriophage composition | |
JPH04502260A (en) | N-acetylmuramidase M1 | |
US5856178A (en) | DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same | |
Wilson et al. | Milk-derived antimicrobial peptides to protect against Neonatal Diarrheal Disease: An alternative to antibiotics | |
EP0914456B1 (en) | Gene expression in monocytes and macrophages | |
US7223412B1 (en) | Staphylococcal enterotoxin SEC-SER, expression vector and host cell, production method thereof, and manufacturing method of vaccine | |
WO2021157732A1 (en) | Agent for use with bacteriophage | |
AU2562300A (en) | Adjuvant and cell maturation agent | |
KR19980701695A (en) | A therapeutic agent for atherosclerosis comprising recombinant DNA in which DNA encoding myosin heavy chain SM1 isoform protein is inserted into vector DNA, microorganisms into which the recombinant DNA is introduced, and recombinant DNA | |
Vespa | Mechanism of continuous IA expression by murine macrophages obtained from peritoneal exudates | |
KR20040103941A (en) | Microorganism for genetic therapeutic teatment of proliferative diseases | |
CAMBRIDGE et al. | Patent bibliography |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971107 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20001214 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: IMMUNOPHARMA INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030204 |